| Mayo Clinic | 60.0 | 4 | 0 |
| Cleveland Clinic | 60.0 | 4 | 0 |
| Human Resource Management Review | 60.0 | 4 | 0 |
| American journal of contact dermatitis : official journal of the American Contact Dermatitis Society | 54.3 | 1 | 3 |
| National Institute for Occupational Safety and Health | 51.7 | 3 | 0 |
| Q229883 | 51.7 | 3 | 0 |
| The Cigna Group | 51.7 | 3 | 0 |
| Brain and Language | 51.7 | 3 | 0 |
| Epilepsy Currents | 51.7 | 3 | 0 |
| Virology | 51.7 | 3 | 0 |
| Applied Mathematics and Computation | 51.7 | 3 | 0 |
| Advances in Virus Research | 51.7 | 3 | 0 |
| Advances in Parasitology | 51.7 | 3 | 0 |
| American Journal of Managed Care | 51.7 | 3 | 0 |
| Vital and health statistics. Series 21, Data on natality, marriage, and divorce | 51.7 | 3 | 0 |
| Vital and health statistics. Series 5, Comparative international vital and health statistics reports | 51.7 | 3 | 0 |
| Harvard men's health watch | 51.7 | 3 | 0 |
| Harvard women's health watch | 51.7 | 3 | 0 |
| Chronic Diseases and Translational Medicine | 51.7 | 3 | 0 |
| World Journal of Otorhinolaryngology-Head and Neck Surgery | 51.7 | 3 | 0 |
| Office of Readiness and Response | 51.7 | 3 | 0 |
| Clinical trial NCT07597382 | 51.7 | 3 | 0 |
| Clinical trial NCT07585825 | 51.7 | 3 | 0 |
| Clinical trial NCT07571616 | 51.7 | 3 | 0 |
| Clinical trial NCT07571629 | 51.7 | 3 | 0 |
| Clinical trial NCT07611032 | 51.7 | 3 | 0 |
| Wave Motion | 41.0 | 2 | 0 |
| Ultrasonics Sonochemistry | 41.0 | 2 | 0 |
| University of Pennsylvania | 41.0 | 2 | 0 |
| Massachusetts General Hospital | 41.0 | 2 | 0 |
| Nucleic Acids Research | 41.0 | 2 | 0 |
| United Methodist Church | 41.0 | 2 | 0 |
| Clinical Genitourinary Cancer | 41.0 | 2 | 0 |
| Journal of Economic Theory | 41.0 | 2 | 0 |
| Blood | 41.0 | 2 | 0 |
| Tetrahedron Letters | 41.0 | 2 | 0 |
| Nuclear Physics | 41.0 | 2 | 0 |
| The University of Texas MD Anderson Cancer Center | 41.0 | 2 | 0 |
| Trends in Cell Biology | 41.0 | 2 | 0 |
| Intelligence | 41.0 | 2 | 0 |
| Journal of Operations Management | 41.0 | 2 | 0 |
| Brachytherapy | 41.0 | 2 | 0 |
| Mechanisms of Ageing and Development | 41.0 | 2 | 0 |
| Trends in Cardiovascular Medicine | 41.0 | 2 | 0 |
| Seminars in Cancer Biology | 41.0 | 2 | 0 |
| Journal of Crystal Growth | 41.0 | 2 | 0 |
| Field Crops Research | 41.0 | 2 | 0 |
| Cardiovascular Pathology | 41.0 | 2 | 0 |
| Biophysical Journal | 41.0 | 2 | 0 |
| Physica C | 41.0 | 2 | 0 |
| Computer Communications | 41.0 | 2 | 0 |
| Robotics and Autonomous Systems | 41.0 | 2 | 0 |
| Marine Micropaleontology | 41.0 | 2 | 0 |
| Comptes Rendus. Biologies | 41.0 | 2 | 0 |
| Mathematical Biosciences | 41.0 | 2 | 0 |
| International Journal of Medical Informatics | 41.0 | 2 | 0 |
| Postharvest Biology and Technology | 41.0 | 2 | 0 |
| Nuclear Physics A | 41.0 | 2 | 0 |
| Toxicological Sciences | 41.0 | 2 | 0 |
| Toxicology and Applied Pharmacology | 41.0 | 2 | 0 |
| Advances in Agronomy | 41.0 | 2 | 0 |
| Cancer Detection and Prevention | 41.0 | 2 | 0 |
| Cancer Radiothérapie | 41.0 | 2 | 0 |
| Epi Info | 41.0 | 2 | 0 |
| Microelectronic Engineering | 41.0 | 2 | 0 |
| Optical Switching and Networking | 41.0 | 2 | 0 |
| Journal of Communication Disorders | 41.0 | 2 | 0 |
| Agricultural Systems | 41.0 | 2 | 0 |
| Applied Catalysis A: General | 41.0 | 2 | 0 |
| Applied Clay Science | 41.0 | 2 | 0 |
| International Review of Cytology | 41.0 | 2 | 0 |
| International Journal of Obstetric Anesthesia | 41.0 | 2 | 0 |
| Nuclear Physics B | 41.0 | 2 | 0 |
| Annales pharmaceutiques françaises | 41.0 | 2 | 0 |
| Coordination Chemistry Reviews | 41.0 | 2 | 0 |
| Food Chemistry | 41.0 | 2 | 0 |
| Journal of Molecular Structure | 41.0 | 2 | 0 |
| Journal of the American Society for Mass Spectrometry | 41.0 | 2 | 0 |
| Electrochemistry Communications | 41.0 | 2 | 0 |
| Fuel Processing Technology | 41.0 | 2 | 0 |
| National Education Association | 41.0 | 2 | 0 |
| Advances in Cancer Research | 41.0 | 2 | 0 |
| Journal of Fluorine Chemistry | 41.0 | 2 | 0 |
| Journal of Pharmaceutical Sciences | 41.0 | 2 | 0 |
| Microporous and Mesoporous Materials | 41.0 | 2 | 0 |
| Progress in Solid State Chemistry | 41.0 | 2 | 0 |
| Radiation Physics and Chemistry | 41.0 | 2 | 0 |
| Vibrational Spectroscopy | 41.0 | 2 | 0 |
| Physiology & Behavior | 41.0 | 2 | 0 |
| Vacuum | 41.0 | 2 | 0 |
| Computers and Electronics in Agriculture | 41.0 | 2 | 0 |
| Advances in Mathematics | 41.0 | 2 | 0 |
| American Journal of Preventive Medicine | 41.0 | 2 | 0 |
| American Journal of Translational Research | 41.0 | 2 | 0 |
| Biomedical Optics Express | 41.0 | 2 | 0 |
| Blue Cross Blue Shield Association | 41.0 | 2 | 0 |
| Boston Medical Center | 41.0 | 2 | 0 |
| Brain Research | 41.0 | 2 | 0 |
| China Economic Review | 41.0 | 2 | 0 |
| ClinicalTrials.gov | 41.0 | 2 | 0 |
| Cultural Diversity and Ethnic Minority Psychology | 41.0 | 2 | 0 |
| dbSNP | 41.0 | 2 | 0 |
| Duke University Health System | 41.0 | 2 | 0 |
| Early Childhood Research Quarterly | 41.0 | 2 | 0 |
| Everyday Health | 41.0 | 2 | 0 |
| Experimental Hematology | 41.0 | 2 | 0 |
| Geochimica et Cosmochimica Acta | 41.0 | 2 | 0 |
| H. Lee Moffitt Cancer Center & Research Institute | 41.0 | 2 | 0 |
| Journal of Memory and Language | 41.0 | 2 | 0 |
| Journal of Second Language Writing | 41.0 | 2 | 0 |
| Journal of Sound and Vibration | 41.0 | 2 | 0 |
| Journal of the Academy of Nutrition and Dietetics | 41.0 | 2 | 0 |
| Laboratory Investigation | 41.0 | 2 | 0 |
| Learning and Individual Differences | 41.0 | 2 | 0 |
| Magnetic Resonance Imaging | 41.0 | 2 | 0 |
| Museum Management and Curatorship | 41.0 | 2 | 0 |
| Personality and Individual Differences | 41.0 | 2 | 0 |
| Preventing Chronic Disease | 41.0 | 2 | 0 |
| Quaternary Research | 41.0 | 2 | 0 |
| Western Journal of Medicine | 41.0 | 2 | 0 |
| Transplantation Proceedings | 41.0 | 2 | 0 |
| Trends in Amplification | 41.0 | 2 | 0 |
| Ulster Medical Journal | 41.0 | 2 | 0 |
| University of Pittsburgh Medical Center | 41.0 | 2 | 0 |
| UpToDate | 41.0 | 2 | 0 |
| Vaccine Research Center | 41.0 | 2 | 0 |
| The AAPS Journal | 41.0 | 2 | 0 |
| Finite Elements in Analysis and Design | 41.0 | 2 | 0 |
| Linear Algebra and its Applications | 41.0 | 2 | 0 |
| Annales de l'Institut Henri Poincare C | 41.0 | 2 | 0 |
| Applied Mathematics Letters | 41.0 | 2 | 0 |
| Applied Numerical Mathematics | 41.0 | 2 | 0 |
| Current Opinion in Genetics & Development | 41.0 | 2 | 0 |
| Journal of Fluency Disorders | 41.0 | 2 | 0 |
| Nonlinear Analysis | 41.0 | 2 | 0 |
| Nuclear Instruments & Methods in Physics Research B | 41.0 | 2 | 0 |
| Rice | 41.0 | 2 | 0 |
| Seminars in Cell & Developmental Biology | 41.0 | 2 | 0 |
| Systems & Control Letters | 41.0 | 2 | 0 |
| NeuroToxicology | 41.0 | 2 | 0 |
| Differential Geometry and its Applications | 41.0 | 2 | 0 |
| Journal of Combinatorial Theory, Series B | 41.0 | 2 | 0 |
| Journal of Mathematical Analysis and Applications | 41.0 | 2 | 0 |
| Journal of Web Semantics | 41.0 | 2 | 0 |
| Pathophysiology | 41.0 | 2 | 0 |
| BJOG: an International Journal of Obstetrics and Gynaecology | 41.0 | 2 | 0 |
| Cancer Control | 41.0 | 2 | 0 |
| Archives of Gerontology and Geriatrics | 41.0 | 2 | 0 |
| Cryptogamie Bryologie | 41.0 | 2 | 0 |
| Advances in Marine Biology | 41.0 | 2 | 0 |
| BBA: Molecular Basis of Disease | 41.0 | 2 | 0 |
| Global Finance Journal | 41.0 | 2 | 0 |
| Advances in Carbohydrate Chemistry and Biochemistry | 41.0 | 2 | 0 |
| AAPS PharmSciTech | 41.0 | 2 | 0 |
| Brain and Development | 41.0 | 2 | 0 |
| Cryptogamie Algologie | 41.0 | 2 | 0 |
| Aggression and Violent Behavior | 41.0 | 2 | 0 |
| Pediatric Neurology | 41.0 | 2 | 0 |
| General Hospital Psychiatry | 41.0 | 2 | 0 |
| Comparative Immunology, Microbiology & Infectious Diseases | 41.0 | 2 | 0 |
| International Journal of Mental Health Systems | 41.0 | 2 | 0 |
| Advances in Applied Microbiology | 41.0 | 2 | 0 |
| Optometry - Journal of the American Optometric Association | 41.0 | 2 | 0 |
| Journal of Policy Modeling | 41.0 | 2 | 0 |
| Best Practice and Research: Clinical Gastroenterology | 41.0 | 2 | 0 |
| International Journal of Law and Psychiatry | 41.0 | 2 | 0 |
| Prostaglandins and Other Lipid Mediators | 41.0 | 2 | 0 |
| Building and Environment | 41.0 | 2 | 0 |
| Industrial Marketing Management | 41.0 | 2 | 0 |
| Meat Science | 41.0 | 2 | 0 |
| Research in Organizational Behavior | 41.0 | 2 | 0 |
| Fish and Shellfish Immunology | 41.0 | 2 | 0 |
| Journal of Immunological Methods | 41.0 | 2 | 0 |
| Human Pathology | 41.0 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology | 41.0 | 2 | 0 |
| The History of the Family | 41.0 | 2 | 0 |
| Journal of Environmental Management | 41.0 | 2 | 0 |
| Insight | 41.0 | 2 | 0 |
| Business Horizons | 41.0 | 2 | 0 |
| Computers in Human Behavior | 41.0 | 2 | 0 |
| Government Information Quarterly | 41.0 | 2 | 0 |
| Linguistics and Education | 41.0 | 2 | 0 |
| Cryptogamie Mycologie | 41.0 | 2 | 0 |
| Behaviour Research and Therapy | 41.0 | 2 | 0 |
| Advances in Botanical Research | 41.0 | 2 | 0 |
| Journal of Urban Health | 41.0 | 2 | 0 |
| Comptes Rendus. Géoscience | 41.0 | 2 | 0 |
| Neural Development | 41.0 | 2 | 0 |
| Socio-Economic Planning Sciences | 41.0 | 2 | 0 |
| Organizational Dynamics | 41.0 | 2 | 0 |
| The American Journal of Surgery | 41.0 | 2 | 0 |
| Clinical Neurophysiology | 41.0 | 2 | 0 |
| Ocean Engineering | 41.0 | 2 | 0 |
| International Review of Law and Economics | 41.0 | 2 | 0 |
| Nuclear Physics B - Proceedings Supplements | 41.0 | 2 | 0 |
| Revue Europeene de Psychologie Appliquee | 41.0 | 2 | 0 |
| Computers & Graphics | 41.0 | 2 | 0 |
| Patient Care: Topics in Allergy and Immunology | 41.0 | 2 | 0 |
| Journal of African Earth Sciences | 41.0 | 2 | 0 |
| Journal of the Society of Laparoendoscopic Surgeons | 41.0 | 2 | 0 |
| Annual Reports in Medicinal Chemistry | 41.0 | 2 | 0 |
| Comparative Biochemistry and Physiology. Part D: Genomics and Proteomics | 41.0 | 2 | 0 |
| European Journal of Mechanics A - Solids | 41.0 | 2 | 0 |
| Computers and Composition | 41.0 | 2 | 0 |
| Review of Financial Economics | 41.0 | 2 | 0 |
| Maturitas | 41.0 | 2 | 0 |
| Financial Services Review | 41.0 | 2 | 0 |
| Mechanics Research Communications | 41.0 | 2 | 0 |
| Journal of Cultural Heritage | 41.0 | 2 | 0 |
| Clinical Imaging | 41.0 | 2 | 0 |
| Journal of Environmental Sciences | 41.0 | 2 | 0 |
| Journal of Clinical Lipidology | 41.0 | 2 | 0 |
| Journal of Orthopaedics, Trauma and Rehabilitation | 41.0 | 2 | 0 |
| Ticks and Tick-borne Diseases | 41.0 | 2 | 0 |
| The Electricity Journal | 41.0 | 2 | 0 |
| Social Science Research | 41.0 | 2 | 0 |
| Archives of Cardiovascular Diseases Supplements | 41.0 | 2 | 0 |
| HealthGrades | 41.0 | 2 | 0 |
| National Survey of Family Growth | 41.0 | 2 | 0 |
| National Vital Statistics System | 41.0 | 2 | 0 |
| NIOSH Power Tools Database | 41.0 | 2 | 0 |
| UCLA Health System | 41.0 | 2 | 0 |
| Q20641742 | 41.0 | 2 | 0 |
| Advances in Nutrition | 41.0 | 2 | 0 |
| Oregon Graduate Center | 41.0 | 2 | 0 |
| Morbidity and Mortality Weekly Report: Recommendations and Reports | 41.0 | 2 | 0 |
| Filtration & Separation | 41.0 | 2 | 0 |
| Fundamental and Applied Toxicology | 41.0 | 2 | 0 |
| Journal of the Less Common Metals | 41.0 | 2 | 0 |
| Scripta Metallurgica | 41.0 | 2 | 0 |
| Diseases of the chest | 41.0 | 2 | 0 |
| Chemical health & safety American Chemical Society, Division of Chemical Health and Safety | 41.0 | 2 | 0 |
| Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo | 41.0 | 2 | 0 |
| Behavioral Biology | 41.0 | 2 | 0 |
| The Journal of clinical and aesthetic dermatology | 41.0 | 2 | 0 |
| Alcohol research : current reviews | 41.0 | 2 | 0 |
| Cell Biology International Reports | 41.0 | 2 | 0 |
| Vital & health statistics. Series 3, Analytical and epidemiological studies | 41.0 | 2 | 0 |
| Dermato-endocrinology | 41.0 | 2 | 0 |
| British Heart Journal | 41.0 | 2 | 0 |
| The western journal of emergency medicine | 41.0 | 2 | 0 |
| Prostate international | 41.0 | 2 | 0 |
| Psychiatry | 41.0 | 2 | 0 |
| Mycobiology | 41.0 | 2 | 0 |
| The Lancet Psychiatry | 41.0 | 2 | 0 |
| Advances in food research | 41.0 | 2 | 0 |
| Science in China. Series B, Chemistry, life sciences & earth sciences | 41.0 | 2 | 0 |
| Genetic analysis, techniques and applications | 41.0 | 2 | 0 |
| Journal of the American Pharmaceutical Association | 41.0 | 2 | 0 |
| Vital and health statistics. Series 3, Analytical studies | 41.0 | 2 | 0 |
| Vital and health statistics. Ser. 4, Documents and committee reports | 41.0 | 2 | 0 |
| Vital and health statistics. Series 13, Data from the National Health Survey | 41.0 | 2 | 0 |
| The Harvard mental health letter | 41.0 | 2 | 0 |
| Journal of epilepsy | 41.0 | 2 | 0 |
| Ethology and sociobiology | 41.0 | 2 | 0 |
| Aging trends (Hyattsville, Md.) | 41.0 | 2 | 0 |
| Clinical microbiology newsletter | 41.0 | 2 | 0 |
| NCHS data brief | 41.0 | 2 | 0 |
| Journal of Verbal Learning and Verbal Behavior | 41.0 | 2 | 0 |
| Paediatrics and Child Health | 41.0 | 2 | 0 |
| The Lancet: Diabetes & Endocrinology | 41.0 | 2 | 0 |
| Avian Research | 41.0 | 2 | 0 |
| Alzheimer's & dementia (Amsterdam, Netherlands) | 41.0 | 2 | 0 |
| Cell Chemical Biology | 41.0 | 2 | 0 |
| MMWR supplements | 41.0 | 2 | 0 |
| Clinical neurophysiology practice | 41.0 | 2 | 0 |
| Information and control | 41.0 | 2 | 0 |
| Studies in Logic and the Foundations of Mathematics | 41.0 | 2 | 0 |
| Computing systems in engineering : an international journal | 41.0 | 2 | 0 |
| National Center for Emerging and Zoonotic Infectious Diseases | 41.0 | 2 | 0 |
| Division of Parasitic Diseases and Malaria | 41.0 | 2 | 0 |
| Advanced Dermatology & Cosmetic Surgery | 41.0 | 2 | 0 |
| Chronic Disease Prevention and Health Promotion | 41.0 | 2 | 0 |
| UPMC Health System | 41.0 | 2 | 0 |
| UH Cleveland Medical Center | 41.0 | 2 | 0 |
| The Journal of Finance and Data Science | 41.0 | 2 | 0 |
| CaosDB - Research Data Management for Complex, Changing, and Automated Research Workflows | 41.0 | 2 | 0 |
| Johns Hopkins Medicine | 41.0 | 2 | 0 |
| Journal of Urban Management | 41.0 | 2 | 0 |
| Journal of Asian Ceramic Societies | 41.0 | 2 | 0 |
| Climate Risk Management | 41.0 | 2 | 0 |
| Information Processing in Agriculture | 41.0 | 2 | 0 |
| Advances in Inorganic Chemistry and Radiochemistry | 41.0 | 2 | 0 |
| Fish Physiology | 41.0 | 2 | 0 |
| Computer Vision, Graphics, and Image Processing | 41.0 | 2 | 0 |
| Network Security | 41.0 | 2 | 0 |
| Inorganic and Nuclear Chemistry Letters | 41.0 | 2 | 0 |
| Inorganica Chimica Acta Reviews | 41.0 | 2 | 0 |
| Information Storage and Retrieval | 41.0 | 2 | 0 |
| bidirectional encoder representations from transformers | 41.0 | 2 | 0 |
| Biometric Technology Today | 41.0 | 2 | 0 |
| Membrane Technology | 41.0 | 2 | 0 |
| Filtration Industry Analyst | 41.0 | 2 | 0 |
| Fuel Cells Bulletin | 41.0 | 2 | 0 |
| Journal of Patient Safety & Infection Control | 41.0 | 2 | 0 |
| Pump Industry Analyst | 41.0 | 2 | 0 |
| Space Research Today | 41.0 | 2 | 0 |
| World Pumps | 41.0 | 2 | 0 |
| Patient Education and Counseling | 40.1 | 1 | 1 |
| Schweiger Dermatology Group (United States) | 40.1 | 1 | 1 |
| La Roche-Posay | 40.0 | 0 | 6 |
| Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis | 28.5 | 0 | 3 |
| Atopic Dermatitis: Skin-Directed Management | 28.5 | 0 | 3 |
| Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair | 28.5 | 0 | 3 |
| The first Australian Baseline Series: Recommendations for patch testing in suspected contact dermatitis | 28.5 | 0 | 3 |
| Efficacy of a Moisturizing Foam in Skin Barrier Regeneration and Itch Relief in Subjects Prone to Atopic Dermatitis | 28.5 | 0 | 3 |
| Case studies assessing a new skin barrier repair cream for the treatment of atopic dermatitis | 28.5 | 0 | 3 |
| Patch testing with dermatophagoides and its correlation with chronic eczema and atopic dermatitis. | 28.5 | 0 | 3 |
| Severe skin inflammation and filaggrin mutation similarly alter the skin barrier in patients with atopic dermatitis | 28.5 | 0 | 3 |
| Sesquiterpene lactone mix patch testing supplemented with dandelion extract in patients with allergic contact dermatitis, atopic dermatitis and non-allergic chronic inflammatory skin diseases | 28.5 | 0 | 3 |
| Sensitive skin is highly frequent in extrinsic atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier impairment | 28.5 | 0 | 3 |
| Effects of Systematic Patient Education in Skin Care and Protection in a Hand Eczema Clinic | 28.5 | 0 | 3 |
| Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product | 28.5 | 0 | 3 |
| Evaluation of skin barrier function in allergic contact dermatitis and atopic dermatitis using method of the continuous TEWL measurement | 28.5 | 0 | 3 |
| Approaching atopic dermatitis treatment differently: from skin barrier preservation to allergen-specific immunotherapy | 28.5 | 0 | 3 |
| Canadian Consensus on Skin Barrier Repair Therapy in Atopic Dermatitis | 28.5 | 0 | 3 |
| The impact of dupilumab on patch testing and the prevalence of comorbid allergic contact dermatitis in recalcitrant atopic dermatitis: A retrospective chart review | 28.5 | 0 | 3 |
| Variable impact of dupilumab on patch testing results and allergic contact dermatitis in adults with atopic dermatitis | 28.5 | 0 | 3 |
| Factors influencing the occurrence of hand eczema in adults with a history of atopic dermatitis in childhood | 28.5 | 0 | 3 |
| Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas | 28.5 | 0 | 3 |
| Role of Antimicrobial Peptides in Skin Barrier Repair in Individuals with Atopic Dermatitis | 28.5 | 0 | 3 |
| Exploring the relationship between allergic contact dermatitis and atopic dermatitis in children: insights from a retrospective patch testing analysis | 28.5 | 0 | 3 |
| 682 Induction of keratin 1 and keratin 10 expression by topical glucose in a mouse model of atopic dermatitis and in keratinocyte culture: A possible role of glucose in skin barrier repair | 28.5 | 0 | 3 |
| atopic dermatitis | 22.6 | 0 | 2 |
| rash | 22.6 | 0 | 2 |
| miliaria | 22.6 | 0 | 2 |
| hand eczema | 22.6 | 0 | 2 |
| No7 product line | 22.6 | 0 | 2 |
| Chemical assessment of "In-Use" allergic contact dermatitis patch test reagents from dermatology clinics | 22.6 | 0 | 2 |
| Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis? | 22.6 | 0 | 2 |
| Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Epidermal Permeability Barrier Defects and Barrier Repair Therapy in Atopic Dermatitis | 22.6 | 0 | 2 |
| Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis, and seborrheic dermatitis | 22.6 | 0 | 2 |
| A review of perineal skin care protocols and skin barrier product use | 22.6 | 0 | 2 |
| Contact allergies to topical corticosteroids: 10 cases of contact dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis from topical corticosteroids | 22.6 | 0 | 2 |
| Skin barrier homeostasis in atopic dermatitis: feedback regulation of kallikrein activity | 22.6 | 0 | 2 |
| Skin Barrier Defects in Atopic Dermatitis | 22.6 | 0 | 2 |
| Current trends in patch testing - new data from the German Contact Dermatitis Research Group (DKG) and the Information Network of Departments of Dermatology (IVDK). | 22.6 | 0 | 2 |
| Anogenital dermatitis in patients referred for patch testing: retrospective analysis of cross-sectional data from the North American Contact Dermatitis Group, 1994-2004. | 22.6 | 0 | 2 |
| The value of patch testing patients with a scattered generalized distribution of dermatitis: retrospective cross-sectional analyses of North American Contact Dermatitis Group data, 2001 to 2004. | 22.6 | 0 | 2 |
| An overview of the efficacy of topical corticosteroids in experimental human nickel contact dermatitis | 22.6 | 0 | 2 |
| Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment | 22.6 | 0 | 2 |
| Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. | 22.6 | 0 | 2 |
| Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema | 22.6 | 0 | 2 |
| Noninvasive measuring methods for the investigation of irritant patch test reactions. A study of patients with hand eczema, atopic dermatitis and controls | 22.6 | 0 | 2 |
| Occupation-related contact dermatitis in North American health care workers referred for patch testing: cross-sectional data, 1998 to 2004. | 22.6 | 0 | 2 |
| Contact allergy in children referred for patch testing: North American Contact Dermatitis Group data, 2001-2004. | 22.6 | 0 | 2 |
| Aeroallergen patch testing in patients of suspected contact dermatitis | 22.6 | 0 | 2 |
| CX₃CL1 (fractalkine) and its receptor CX₃CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin | 22.6 | 0 | 2 |
| Atopic Dermatitis-like Graft-versus-host Disease and Lichen Planus-like Graft-versus-host Disease: Alterations in Skin Barrier Function and Related Molecules | 22.6 | 0 | 2 |
| Abnormal skin barrier in the etiopathogenesis of atopic dermatitis | 22.6 | 0 | 2 |
| Patient education in the long-term management of atopic dermatitis. | 22.6 | 0 | 2 |
| Sensitive Skin: Assessment of the Skin Barrier Using Confocal Raman Microspectroscopy. | 22.6 | 0 | 2 |
| Adhesion molecule profiles in atopic dermatitis vs. allergic contact dermatitis: pharmacological modulation by cetirizine | 22.6 | 0 | 2 |
| Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids | 22.6 | 0 | 2 |
| Patch testing with fragrances: results of a multicenter study of the European Environmental and Contact Dermatitis Research Group with 48 frequently used constituents of perfumes | 22.6 | 0 | 2 |
| Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis | 22.6 | 0 | 2 |
| Effect of standardized skin care regimens on neonatal skin barrier function in different body areas | 22.6 | 0 | 2 |
| Patch testing in atopic dermatitis. | 22.6 | 0 | 2 |
| Hepatitis Due to Mycophenolate Mofetil Used to Treat Atopic Dermatitis and Allergic Contact Dermatitis | 22.6 | 0 | 2 |
| Patch testing in suspected allergic contact dermatitis to cosmetics | 22.6 | 0 | 2 |
| Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention | 22.6 | 0 | 2 |
| Effect of olive and sunflower seed oil on the adult skin barrier: implications for neonatal skin care | 22.6 | 0 | 2 |
| A systematic review of contact dermatitis treatment and prevention | 22.6 | 0 | 2 |
| Risk for hand eczema in employees with past or present atopic dermatitis | 22.6 | 0 | 2 |
| Topically applied ZnO nanoparticles suppress allergen induced skin inflammation but induce vigorous IgE production in the atopic dermatitis mouse model | 22.6 | 0 | 2 |
| The role of patch testing for chemical and protein allergens in atopic dermatitis. | 22.6 | 0 | 2 |
| Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation | 22.6 | 0 | 2 |
| Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation | 22.6 | 0 | 2 |
| Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial | 22.6 | 0 | 2 |
| Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitis | 22.6 | 0 | 2 |
| The utility of patch testing children with atopic dermatitis | 22.6 | 0 | 2 |
| Toll-like receptor 3 activation is required for normal skin barrier repair following UV damage | 22.6 | 0 | 2 |
| Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis | 22.6 | 0 | 2 |
| Dexpanthenol enhances skin barrier repair and reduces inflammation after sodium lauryl sulphate-induced irritation | 22.6 | 0 | 2 |
| Atopic dermatitis: a disease of altered skin barrier and immune dysregulation | 22.6 | 0 | 2 |
| The skin barrier and use of moisturizers in atopic dermatitis | 22.6 | 0 | 2 |
| The relationship between atopic dermatitis and contact dermatitis | 22.6 | 0 | 2 |
| Patch testing for allergic contact dermatitis in the allergist office | 22.6 | 0 | 2 |
| A pilot study of emollient therapy for the primary prevention of atopic dermatitis | 22.6 | 0 | 2 |
| Skin barrier dysfunction measured by transepidermal water loss at 2 days and 2 months predates and predicts atopic dermatitis at 1 year | 22.6 | 0 | 2 |
| Review: Pathogenesis of canine atopic dermatitis: skin barrier and host-micro-organism interaction. | 22.6 | 0 | 2 |
| Still elusive relationship between atopic dermatitis and allergic contact dermatitis. | 22.6 | 0 | 2 |
| Pruni cortex ameliorates skin inflammation possibly through HMGB1-NFκB pathway in house dust mite induced atopic dermatitis NC/Nga transgenic mice | 22.6 | 0 | 2 |
| Lessons from atopy patch testing in atopic dermatitis | 22.6 | 0 | 2 |
| Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. | 22.6 | 0 | 2 |
| Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus | 22.6 | 0 | 2 |
| Multiple pathways driving IgE production and chronic dermatitis in mice: a model for atopic dermatitis? | 22.6 | 0 | 2 |
| Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis | 22.6 | 0 | 2 |
| Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis | 22.6 | 0 | 2 |
| Patch testing in Iranian children with allergic contact dermatitis | 22.6 | 0 | 2 |
| A Pragmatic Approach to Patch Testing Atopic Dermatitis Patients: Clinical Recommendations Based on Expert Consensus Opinion. | 22.6 | 0 | 2 |
| Do Early Skin Care Practices Alter the Risk of Atopic Dermatitis? A Case‐Control Study | 22.6 | 0 | 2 |
| Pediatric Contact Dermatitis Registry Data on Contact Allergy in Children With Atopic Dermatitis | 22.6 | 0 | 2 |
| Occupational Contact Dermatitis in North American Print Machine Operators Referred for Patch Testing: Retrospective Analysis of Cross-Sectional Data From the North American Contact Dermatitis Group 1998 to 2014. | 22.6 | 0 | 2 |
| Occupational Contact Dermatitis in North American Production Workers Referred for Patch Testing: Retrospective Analysis of Cross-Sectional Data From the North American Contact Dermatitis Group 1998 to 2014. | 22.6 | 0 | 2 |
| Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen | 22.6 | 0 | 2 |
| Skin care education and individual counselling versus treatment as usual in healthcare workers with hand eczema: randomised clinical trial. | 22.6 | 0 | 2 |
| Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan | 22.6 | 0 | 2 |
| Skin barrier function in atopic dermatitis | 22.6 | 0 | 2 |
| Skin barrier function and dermal inflammation. An experimental study of transepidermal water loss after dermal tuberculin injection compared with SLS patch testing | 22.6 | 0 | 2 |
| Barrier repair trumps immunology in the pathogenesis and therapy of atopic dermatitis | 22.6 | 0 | 2 |
| A prospective study of atopic dermatitis managed without topical corticosteroids for a 6-month period | 22.6 | 0 | 2 |
| NOD2 and TLR2 ligands trigger the activation of basophils and eosinophils by interacting with dermal fibroblasts in atopic dermatitis-like skin inflammation | 22.6 | 0 | 2 |
| Atopic dermatitis, patch testing, and house dust mites: a brief review | 22.6 | 0 | 2 |
| Gentle cleansing and moisturizing for patients with atopic dermatitis and sensitive skin | 22.6 | 0 | 2 |
| Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption | 22.6 | 0 | 2 |
| Expression of COUP-TF-interacting protein 2 (CTIP2) in human atopic dermatitis and allergic contact dermatitis skin | 22.6 | 0 | 2 |
| Application of Topical Acids Improves Atopic Dermatitis in Murine Model by Enhancement of Skin Barrier Functions Regardless of the Origin of Acids | 22.6 | 0 | 2 |
| Accumulation of Metal-Specific T Cells in Inflamed Skin in a Novel Murine Model of Chromium-Induced Allergic Contact Dermatitis | 22.6 | 0 | 2 |
| Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: overview of the pathophysiology of atopic dermatitis | 22.6 | 0 | 2 |
| Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment:keratinocytes in atopic dermatitis - their pathogenic involvement. | 22.6 | 0 | 2 |
| Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: mechanisms and management of itch in atopic dermatitis | 22.6 | 0 | 2 |
| Skin barrier breakdown: a renaissance in emollient therapy. | 22.6 | 0 | 2 |
| An Appropriate Response to the Black-Box Warning: Corrective, Barrier Repair Therapy in Atopic Dermatitis. | 22.6 | 0 | 2 |
| The effectiveness of a skin care program for the prevention of contact dermatitis in health care workers (the Healthy Hands Project): study protocol for a cluster randomized controlled trial | 22.6 | 0 | 2 |
| The diagnostic value of atopy patch testing and prick testing in atopic dermatitis: facts and controversies | 22.6 | 0 | 2 |
| Impact of atopic dermatitis and loss-of-function mutations in the filaggrin gene on the development of occupational irritant contact dermatitis | 22.6 | 0 | 2 |
| Unravelling the skin barrier: a new paradigm for atopic dermatitis and house dust mites | 22.6 | 0 | 2 |
| Skin barrier in atopic dermatitis. | 22.6 | 0 | 2 |
| Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids | 22.6 | 0 | 2 |
| Patch testing in atopic dermatitis patients. | 22.6 | 0 | 2 |
| Atopic dermatitis: current options and treatment plan | 22.6 | 0 | 2 |
| Current evidence of skin barrier dysfunction in human and canine atopic dermatitis | 22.6 | 0 | 2 |
| The Antimicrobial Skin Barrier in Patients with Atopic Dermatitis | 22.6 | 0 | 2 |
| Propylene glycol: an often unrecognized cause of allergic contact dermatitis in patients using topical corticosteroids | 22.6 | 0 | 2 |
| Papulosquamous disorders: atopic dermatitis, psoriasis, seborrheic dermatitis, and nickel contact dermatitis | 22.6 | 0 | 2 |
| Is the skin barrier abnormal in dogs with atopic dermatitis? | 22.6 | 0 | 2 |
| Allergic contact dermatitis to nickel in children with atopic dermatitis | 22.6 | 0 | 2 |
| Wet dressing therapy in conjunction with topical corticosteroids is effective for rapid control of severe pediatric atopic dermatitis: experience with 218 patients over 30 years at Mayo Clinic | 22.6 | 0 | 2 |
| A multi-center, retrospective review of patch testing for contact dermatitis in allergy practices | 22.6 | 0 | 2 |
| Therapeutic Patient Education in Children with Atopic Dermatitis: Position Paper on Objectives and Recommendations | 22.6 | 0 | 2 |
| New Insights into Atopic Dermatitis: Role of Skin Barrier and Immune Dysregulation | 22.6 | 0 | 2 |
| Barrier Repair Therapy in Atopic Dermatitis: An Overview | 22.6 | 0 | 2 |
| Clinical relevance of skin barrier changes associated with the use of oral isotretinoin: the importance of barrier repair therapy in patient management | 22.6 | 0 | 2 |
| Atopic dermatitis, and the role for a ceramide-dominant, physiologic lipid-based barrier repair emulsion | 22.6 | 0 | 2 |
| Role of Th17 Cells in Skin Inflammation of Allergic Contact Dermatits | 22.6 | 0 | 2 |
| Update on the Structure and Function of the Skin Barrier: Atopic Dermatitis as an Exemplar of Clinical Implications | 22.6 | 0 | 2 |
| Basics of Patch Testing for Allergic Contact Dermatitis | 22.6 | 0 | 2 |
| Skin barrier in atopic dermatitis. | 22.6 | 0 | 2 |
| Immunological and molecular targets of atopic dermatitis treatment | 22.6 | 0 | 2 |
| Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications | 22.6 | 0 | 2 |
| The Role of Contact Dermatitis in Patients with Atopic Dermatitis | 22.6 | 0 | 2 |
| Current clinical practice in atopic dermatitis | 22.6 | 0 | 2 |
| Eucalyptus oil: contact allergy and safety | 22.6 | 0 | 2 |
| Skin pH Is the Master Switch of Kallikrein 5-Mediated Skin Barrier Destruction in a Murine Atopic Dermatitis Model | 22.6 | 0 | 2 |
| Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? | 22.6 | 0 | 2 |
| A Practical Guide to Patch Testing | 22.6 | 0 | 2 |
| European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice | 22.6 | 0 | 2 |
| EAACI position paper for practical patch testing in allergic contact dermatitis in children. | 22.6 | 0 | 2 |
| Cortisol Homeostasis in the Epidermis is Influenced by Topical Corticosteroids in Patients with Atopic Dermatitis | 22.6 | 0 | 2 |
| Countering Staphylococcus Overgrowth During Patch Testing in Children with Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| Hataedock treatment has preventive therapeutic effects for atopic dermatitis through skin barrier protection in Dermatophagoides farinae-induced NC/Nga mice | 22.6 | 0 | 2 |
| Efficacy and Tolerability of a Cosmetic Skin Care Product With Trans-4-t-butylcyclohexanol and Licochalcone A in Subjects With Sensitive Skin Prone to Redness and Rosacea | 22.6 | 0 | 2 |
| The role of innate lymphoid cells in healthy and inflamed skin | 22.6 | 0 | 2 |
| Stratum Corneum Lipids: Their Role for the Skin Barrier Function in Healthy Subjects and Atopic Dermatitis Patients. | 22.6 | 0 | 2 |
| Biological Variation in Skin Barrier Function: From A (Atopic Dermatitis) to X (Xerosis). | 22.6 | 0 | 2 |
| Coconut oil: The future of atopic dermatitis treatment? | 22.6 | 0 | 2 |
| Anti-inflammatory and anti-allergic effects and underlying mechanisms of Huang-Lian-Jie-Du extract: Implication for atopic dermatitis treatment. | 22.6 | 0 | 2 |
| Vitamin D in atopic dermatitis, chronic urticaria and allergic contact dermatitis | 22.6 | 0 | 2 |
| Wet Wrap Therapy in Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience | 22.6 | 0 | 2 |
| Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. | 22.6 | 0 | 2 |
| Effects of structured patient education in adults with atopic dermatitis: Multicenter randomized controlled trial | 22.6 | 0 | 2 |
| Skin barrier in atopic dermatitis: beyond filaggrin | 22.6 | 0 | 2 |
| Skin Barrier Health: Regulation and Repair of the Stratum Corneum and the Role of Over-the-Counter Skin Care | 22.6 | 0 | 2 |
| Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis. | 22.6 | 0 | 2 |
| Profile of skin barrier proteins and cytokines in adults with atopic dermatitis. | 22.6 | 0 | 2 |
| Exogenous Factors in Skin Barrier Repair | 22.6 | 0 | 2 |
| Efficacy of a Hand Regimen in Skin Barrier Protection in Individuals With Occupational Irritant Contact Dermatitis | 22.6 | 0 | 2 |
| Efficacy of a Skin Condition-Adapted Solution for Xerosis and Itch Relief Associated With Aging | 22.6 | 0 | 2 |
| Oleanolic acid acetate inhibits atopic dermatitis and allergic contact dermatitis in a murine model | 22.6 | 0 | 2 |
| Patch testing, tuberculin testing and sensitization with dinitrochlorobenzene and nitrosodimethylanilini of patients with atopic dermatitis | 22.6 | 0 | 2 |
| Atopic dermatitis treatment: Current state of the art and emerging therapies | 22.6 | 0 | 2 |
| Contact dermatitis considerations in atopic dermatitis | 22.6 | 0 | 2 |
| Hand eczema and long-term prognosis in atopic dermatitis | 22.6 | 0 | 2 |
| Immunofluorescence of the skin in allergic diseases: an investigation of patients with contact dermatitis, allergic vasculitis and atopic dermatitis | 22.6 | 0 | 2 |
| Facial eczema management protocols used on dairy farms in the North Island of New Zealand and associated concentrations of zinc in serum | 22.6 | 0 | 2 |
| Is Food Allergy Testing Reliable in Pediatric Atopic Dermatitis? A Population-Based Study | 22.6 | 0 | 2 |
| Impact of systemic alitretinoin treatment on skin barrier gene and protein expression in patients with chronic hand eczema | 22.6 | 0 | 2 |
| Assessing the readability of skin care and pressure ulcer patient education materials | 22.6 | 0 | 2 |
| Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults | 22.6 | 0 | 2 |
| Patch testing with low molecular oligomers of epoxy resins in humans | 22.6 | 0 | 2 |
| Patch testing and contact allergens in Ethiopia--results of 514 contact dermatitis patients using the European baseline series | 22.6 | 0 | 2 |
| The value of patch testing: a review of 363 cases of allergic contact dermatitis. | 22.6 | 0 | 2 |
| Epidermal Synthesis of Prostaglandins and their Effect on Levels of Cyclic Adenosine 3',5'-Monophosphate | 22.6 | 0 | 2 |
| Atopic dermatitis: skin care and topical therapies | 22.6 | 0 | 2 |
| IL-17 Receptor A Maintains and Protects the Skin Barrier To Prevent Allergic Skin Inflammation. | 22.6 | 0 | 2 |
| Dual-functional transdermal drug delivery system with controllable drug loading based on thermosensitive poloxamer hydrogel for atopic dermatitis treatment. | 22.6 | 0 | 2 |
| Staphylococcus aureus-derived membrane vesicles exacerbate skin inflammation in atopic dermatitis | 22.6 | 0 | 2 |
| Attitudes of Australian dermatologists to the use and safety of topical corticosteroids in paediatric atopic dermatitis | 22.6 | 0 | 2 |
| Patch testing with hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC) - a multicentre study of the Swedish Contact Dermatitis Research Group. | 22.6 | 0 | 2 |
| Atopic dermatitis with severe facial lesions exacerbated by contact dermatitis from topical medicaments | 22.6 | 0 | 2 |
| Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis | 22.6 | 0 | 2 |
| Idiopathic CD4+ lymphocyte deficiency. Report of an unusual case associated with atopic dermatitis and allergic contact dermatitis and review of the literature | 22.6 | 0 | 2 |
| Pilot Study to Evaluate the Effect of Topical Dimethicone on Clinical Signs and Skin Barrier Function in Dogs with Naturally Occurring Atopic Dermatitis | 22.6 | 0 | 2 |
| Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis | 22.6 | 0 | 2 |
| Down-regulation of IL-12 by topical corticosteroids in chronic atopic dermatitis. | 22.6 | 0 | 2 |
| Clinical test with Apolar cream and Calmuril-hydrocortisone cream in contact dermatitis and atopic dermatitis | 22.6 | 0 | 2 |
| Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis | 22.6 | 0 | 2 |
| Onset and severity of atopic dermatitis, atopy and hand eczema in adolescents. | 22.6 | 0 | 2 |
| Chronic finger dermatitis after trauma. Diagnosis: posttraumatic eczema with allergic contact dermatitis to neomycin, bacitracin, and topical corticosteroids | 22.6 | 0 | 2 |
| Contact allergy to topical corticosteroids and systemic contact dermatitis from prednisolone with tolerance of triamcinolone. | 22.6 | 0 | 2 |
| Fluocinonide vs halcinonide in atopic dermatitis. A paired comparison of two potent topical corticosteroids | 22.6 | 0 | 2 |
| Pharmacists' knowledge about use of topical corticosteroids in atopic dermatitis: Pre and post continuing professional development education | 22.6 | 0 | 2 |
| Profiles of selected nutrients affecting skin condition in children with atopic dermatitis | 22.6 | 0 | 2 |
| Conditional knock out of N-WASP in keratinocytes causes skin barrier defects and atopic dermatitis-like inflammation | 22.6 | 0 | 2 |
| Systemic antihistamines--a common outside the guidelines therapeutic strategy in hand eczema management. | 22.6 | 0 | 2 |
| Patch testing for contact dermatitis. | 22.6 | 0 | 2 |
| Effect of skin barrier emulsion cream vs a conventional moisturizer on transepidermal water loss and corneometry in atopic dermatitis: a pilot study | 22.6 | 0 | 2 |
| Hand eczema and atopic dermatitis in adolescents: a prospective cohort study from the BAMSE project. | 22.6 | 0 | 2 |
| Is atopic dermatitis a predisposing factor for experimental acute irritant contact dermatitis? | 22.6 | 0 | 2 |
| Management of Patients with Atopic Dermatitis: The Role of Emollient Therapy | 22.6 | 0 | 2 |
| The effect of long-term feeding of skin barrier-fortified diets on the owner-assessed incidence of atopic dermatitis symptoms in Labrador retrievers | 22.6 | 0 | 2 |
| Allergic Contact Dermatitis: Patch Testing Beyond the TRUE Test. | 22.6 | 0 | 2 |
| Repair and maintenance of the epidermal barrier in patients diagnosed with atopic dermatitis: an evaluation of the components of a body wash-moisturizer skin care regimen directed at management of atopic skin | 22.6 | 0 | 2 |
| A Randomised Controlled Trial to evaluate the effect of a new skin care regimen on skin barrier function in those with podoconiosis in Ethiopia. | 22.6 | 0 | 2 |
| Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study | 22.6 | 0 | 2 |
| Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial | 22.6 | 0 | 2 |
| Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline | 22.6 | 0 | 2 |
| TLR2 and TLR4 expression in atopic dermatitis, contact dermatitis and psoriasis | 22.6 | 0 | 2 |
| Pyrrolidone carboxylic acid levels or caspase-14 expression in the corneocytes of lesional skin correlates with clinical severity, skin barrier function and lesional inflammation in atopic dermatitis | 22.6 | 0 | 2 |
| A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis | 22.6 | 0 | 2 |
| Combined skin prick and patch testing enhances identification of peanut-allergic patients with atopic dermatitis | 22.6 | 0 | 2 |
| Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study | 22.6 | 0 | 2 |
| Patch testing with egg represents a useful integration to diagnosis of egg allergy in children with atopic dermatitis | 22.6 | 0 | 2 |
| Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis: patch testing results at Mount Sinai Medical Center | 22.6 | 0 | 2 |
| Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation. | 22.6 | 0 | 2 |
| Percutaneous absorption of potent topical corticosteroids in patients with severe atopic dermatitis | 22.6 | 0 | 2 |
| Topical corticosteroids in atopic dermatitis | 22.6 | 0 | 2 |
| Stratum corneum TARC level is a new indicator of lesional skin inflammation in atopic dermatitis. | 22.6 | 0 | 2 |
| Patch testing in allergic contact dermatitis: is it useful to perform the cosmetic series in addition to the European standard series? | 22.6 | 0 | 2 |
| Successful treatment of lichen amyloidosus associated with atopic dermatitis using a combination of narrowband ultraviolet B phototherapy, topical corticosteroids and an antihistamine | 22.6 | 0 | 2 |
| Allergic contact dermatitis and systemic contact dermatitis in a patient with polysensitization to topical corticosteroids | 22.6 | 0 | 2 |
| Semipermeable glove membranes--effects on skin barrier repair following SLS irritation | 22.6 | 0 | 2 |
| Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden--with model applications for Denmark, Norway and Finland | 22.6 | 0 | 2 |
| Practical issues for emollient therapy in dry and itchy skin | 22.6 | 0 | 2 |
| Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Ultra-pure soft water improves skin barrier function in children with atopic dermatitis: a randomized, double-blind, placebo-controlled, crossover pilot study. | 22.6 | 0 | 2 |
| Prevalence of foot eczema and associated occupational and non‐occupational factors in patients with hand eczema | 22.6 | 0 | 2 |
| Human β-defensin-2 as a marker for disease severity and skin barrier properties in atopic dermatitis. | 22.6 | 0 | 2 |
| Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). | 22.6 | 0 | 2 |
| Propylene glycol allergic contact dermatitis. A quick reference guide for propylene glycol-free topical corticosteroids in Saudi Arabia | 22.6 | 0 | 2 |
| Perforin and granzyme B may contribute to skin inflammation in atopic dermatitis and psoriasis | 22.6 | 0 | 2 |
| Canine atopic dermatitis: a retrospective study of 266 cases examined at the University of California, Davis, 1992-1998. Part I. Clinical features and allergy testing results | 22.6 | 0 | 2 |
| Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing | 22.6 | 0 | 2 |
| Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: a multicenter study | 22.6 | 0 | 2 |
| Induction of atopic dermatitis-like skin lesion in NC/Nga mice--the influence of the skin barrier destroying solution to the induction of dermatitis | 22.6 | 0 | 2 |
| Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle | 22.6 | 0 | 2 |
| The spectrum of allergic (cross-)sensitivity in clinical patch testing with 'para amino' compounds | 22.6 | 0 | 2 |
| Patch testing for permanent-press allergic contact dermatitis | 22.6 | 0 | 2 |
| Patch testing to exclude allergic contact dermatitis caused by povidone-iodine | 22.6 | 0 | 2 |
| Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity | 22.6 | 0 | 2 |
| Serum IgE levels in atopic dermatitis and in allergic contact dermatitis | 22.6 | 0 | 2 |
| Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema | 22.6 | 0 | 2 |
| P2X purinergic receptor antagonist accelerates skin barrier repair and prevents epidermal hyperplasia induced by skin barrier disruption | 22.6 | 0 | 2 |
| What's new in contact dermatitis: allergy to topical steroids in Israeli patients with contact dermatitis. | 22.6 | 0 | 2 |
| Re-patch testing patients with long-term contact dermatitis | 22.6 | 0 | 2 |
| Allergic Contact Dermatitis in Children With and Without Atopic Dermatitis | 22.6 | 0 | 2 |
| Hydrocortisone-loaded poly(ε-caprolactone) nanoparticles for atopic dermatitis treatment. | 22.6 | 0 | 2 |
| Recovery of a Pharmacologically Active Fatty Acid During the Inflammatory Reaction, Invoked by Patch Testing in Allergic Contact Dermatitis | 22.6 | 0 | 2 |
| Influence of treating atopic dermatitis with oral antihistamine and topical steroids on selected parameters of cell and humoral immunity | 22.6 | 0 | 2 |
| Results of patch testing to personal care product allergens in a standard series and a supplemental cosmetic series: an analysis of 945 patients from the Mayo Clinic Contact Dermatitis Group, 2000-2007. | 22.6 | 0 | 2 |
| Electroporation and ultradeformable liposomes; human skin barrier repair by phospholipid | 22.6 | 0 | 2 |
| The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis | 22.6 | 0 | 2 |
| What do patients with occupational hand eczema know about skin care? | 22.6 | 0 | 2 |
| Artificial disruption of skin barrier prior to irritant patch testing does not improve test design | 22.6 | 0 | 2 |
| Detection of occupational allergic contact dermatitis by patch testing | 22.6 | 0 | 2 |
| Survey of atopic dermatitis and skin barrier functions in Japanese and Chinese school students | 22.6 | 0 | 2 |
| Patch testing of experimentally sensitized beagle dogs: development of a model for skin lesions of atopic dermatitis | 22.6 | 0 | 2 |
| A holistic view on dermatitis: patch testing should be considered in patients with atopic dermatitis. | 22.6 | 0 | 2 |
| Serum leptin level in children with atopic dermatitis-treated topical steroids | 22.6 | 0 | 2 |
| Effect of semipermeable membranes on skin barrier repair following tape stripping | 22.6 | 0 | 2 |
| Occupationally related contact dermatitis in North American food service workers referred for patch testing, 1994 to 2010. | 22.6 | 0 | 2 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial | 22.6 | 0 | 2 |
| Iodopropynylbutyl carbamate 0.2% is suggested for patch testing of patients with eczema possibly related to preservatives | 22.6 | 0 | 2 |
| Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis | 22.6 | 0 | 2 |
| Patch testing in children with hand eczema. A 5-year multicentre study in Spain | 22.6 | 0 | 2 |
| Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial. | 22.6 | 0 | 2 |
| Allergic contact dermatitis in hand eczema | 22.6 | 0 | 2 |
| Atopic dermatitis and contact dermatitis in children | 22.6 | 0 | 2 |
| Rutin suppresses atopic dermatitis and allergic contact dermatitis | 22.6 | 0 | 2 |
| Impact of Patch Testing on Quality of Life in Patients with Hand Eczema: A Follow-up Study | 22.6 | 0 | 2 |
| MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes. | 22.6 | 0 | 2 |
| Daily intake of Jeju groundwater improves the skin condition of the model mouse for human atopic dermatitis | 22.6 | 0 | 2 |
| The effect of topical corticosteroids on bone mineral density in adults with atopic dermatitis | 22.6 | 0 | 2 |
| Atopic dermatitis, filaggrin mutations and irritant contact dermatitis. | 22.6 | 0 | 2 |
| Skin care products can aggravate epidermal function: studies in a murine model suggest a pathogenic role in sensitive skin. | 22.6 | 0 | 2 |
| Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis | 22.6 | 0 | 2 |
| A review of the impact of patch testing on quality of life in allergic contact dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis in Danish children referred for patch testing - a nationwide multicentre study | 22.6 | 0 | 2 |
| Routine patch testing with frullanolide mix: an European Environmental and Contact Dermatitis Research Group multicentre study | 22.6 | 0 | 2 |
| Patch testing in children from 2005 to 2012: results from the North American contact dermatitis group | 22.6 | 0 | 2 |
| Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. | 22.6 | 0 | 2 |
| Lesional elastase activity in psoriasis, contact dermatitis, and atopic dermatitis | 22.6 | 0 | 2 |
| The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial | 22.6 | 0 | 2 |
| Nurses' perceptions of the benefits and adverse effects of hand disinfection: alcohol-based hand rubs vs. hygienic handwashing: a multicentre questionnaire study with additional patch testing by the German Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Poor compliance with topical corticosteroids for atopic dermatitis despite severe disease. | 22.6 | 0 | 2 |
| Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study | 22.6 | 0 | 2 |
| Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: Reactivity to topical preservatives | 22.6 | 0 | 2 |
| Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis | 22.6 | 0 | 2 |
| A method for identifying causative chemicals of allergic contact dermatitis using a combination of chemical analysis and patch testing in patients and animal groups: application to a case of rubber boot dermatitis | 22.6 | 0 | 2 |
| Sensitizing potential of triclosan and triclosan-based skin care products in patients with chronic eczema | 22.6 | 0 | 2 |
| Erythema multiforme-like eruption induced by contact dermatitis caused by topical corticosteroids | 22.6 | 0 | 2 |
| Phenotypical characteristics of the immune cells in allergic contact dermatitis, atopic dermatitis and pityriasis rosea | 22.6 | 0 | 2 |
| Inhibition of skin inflammation and atopic dermatitis by topical application of a novel ceramide derivative, K112PC-5, in mice | 22.6 | 0 | 2 |
| Instant barrier repair: a pilot study investigating occlusion with a new hydrogel patch for the treatment of atopic dermatitis | 22.6 | 0 | 2 |
| Contact dermatitis to pentylene glycol in a prescription cream for atopic dermatitis: case report | 22.6 | 0 | 2 |
| Skin barrier dysfunction in atopic dermatitis | 22.6 | 0 | 2 |
| StabiEL: stabilization of skin condition with Elidel--a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid | 22.6 | 0 | 2 |
| Extracellular superoxide dismutase ameliorates house dust mite‐induced atopic dermatitis‐like skin inflammation and inhibits mast cell activation in mice | 22.6 | 0 | 2 |
| Alleviating the itch-scratch cycle in atopic dermatitis | 22.6 | 0 | 2 |
| Neuroimmunomodulatory compound for sensitive skin care: in vitro and clinical assessment | 22.6 | 0 | 2 |
| Detection of contact hypersensitivity to corticosteroids in allergic contact dermatitis patients who do not respond to topical corticosteroids | 22.6 | 0 | 2 |
| Value of patch testing in atopic dermatitis | 22.6 | 0 | 2 |
| Patch testing for allergic contact dermatitis to cigarettes: Smoked/unsmoked components and formaldehyde factors | 22.6 | 0 | 2 |
| Allergic and photoallergic contact dermatitis from ketoprofen: results of (photo) patch testing and follow-up of 42 patients | 22.6 | 0 | 2 |
| Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis | 22.6 | 0 | 2 |
| A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis | 22.6 | 0 | 2 |
| Opportunities for improving, adapting and introducing emollient therapy and improved newborn skin care practices in Africa | 22.6 | 0 | 2 |
| Comparing the effect of bleach and water baths on skin barrier function in atopic dermatitis: a split‐body randomized controlled trial | 22.6 | 0 | 2 |
| Xerosis is associated with atopic dermatitis, hand eczema and contact sensitization independent of filaggrin gene mutations | 22.6 | 0 | 2 |
| A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids. | 22.6 | 0 | 2 |
| 43 Role of Sweating on Impaired Skin Barrier Functions in Atopic Dermatitis. | 22.6 | 0 | 2 |
| Comparison of atopy patch testing to skin prick testing for diagnosing mite-induced atopic dermatitis: a systematic review and meta-analysis. | 22.6 | 0 | 2 |
| Importance of chamber size for the outcome of atopy patch testing in children with atopic dermatitis and food allergy | 22.6 | 0 | 2 |
| Anti-Inflammatory and Skin Barrier Repair Effects of Topical Application of Some Plant Oils | 22.6 | 0 | 2 |
| Red ginseng extracts attenuate skin inflammation in atopic dermatitis through p70 ribosomal protein S6 kinase activation | 22.6 | 0 | 2 |
| Rapid, successful treatment of atopic dermatitis recalcitrant to topical corticosteroids. | 22.6 | 0 | 2 |
| Therapeutic patient education in children with moderate to severe atopic dermatitis: A multicenter randomized controlled trial in China | 22.6 | 0 | 2 |
| Anti-Inflammatory Activities of Pentaherbs Formula, Berberine, Gallic Acid and Chlorogenic Acid in Atopic Dermatitis-Like Skin Inflammation | 22.6 | 0 | 2 |
| The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis | 22.6 | 0 | 2 |
| Analysis of sensitive skin barrier function: basic indicators and sebum composition | 22.6 | 0 | 2 |
| Patch testing for occupational allergens and the evaluation of patients with occupational contact dermatitis | 22.6 | 0 | 2 |
| Patch testing in Israeli children with suspected allergic contact dermatitis: A retrospective study and literature review. | 22.6 | 0 | 2 |
| Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis | 22.6 | 0 | 2 |
| The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis | 22.6 | 0 | 2 |
| Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation | 22.6 | 0 | 2 |
| Atopic Dermatitis Disease Education | 22.6 | 0 | 2 |
| Atopic dermatitis treatment: what's new on the horizon? | 22.6 | 0 | 2 |
| Atopy patch testing with aeroallergens in patients with atopic dermatitis and controls in Singapore | 22.6 | 0 | 2 |
| Histamine H 4 Receptor Antagonists Ineffective against Itch and Skin Inflammation in Atopic Dermatitis Mouse Model | 22.6 | 0 | 2 |
| Quality of life, anxiety, depression and obsessive‐compulsive tendencies in patients with chronic hand eczema | 22.6 | 0 | 2 |
| Atopic dermatitis: correlation between non-damaged skin barrier function and disease activity | 22.6 | 0 | 2 |
| Applying a vernix caseosa based formulation accelerates skin barrier repair by modulating lipid biosynthesis. | 22.6 | 0 | 2 |
| The cystatin M/E-controlled pathway of skin barrier formation: expression of its key components in psoriasis and atopic dermatitis | 22.6 | 0 | 2 |
| Histomorphology and Immunophenotype of Eczematous Skin Lesions Revisited-Skin Biopsies Are Not Reliable in Differentiating Allergic Contact Dermatitis, Irritant Contact Dermatitis, and Atopic Dermatitis | 22.6 | 0 | 2 |
| Derivation, Evaluation, and Validation of Illustrations of Key Counselling Points for a Pediatric Eczema Action Plan. | 22.6 | 0 | 2 |
| The Future of Atopic Dermatitis Treatment | 22.6 | 0 | 2 |
| Patient education programs for childhood atopic dermatitis: who is interested? | 22.6 | 0 | 2 |
| Interplay between the skin barrier and immune cells in patients with atopic dermatitis unraveled by means of mathematical modeling. | 22.6 | 0 | 2 |
| Impaired responses of peripheral blood mononuclear cells to nickel in patients with nickel-allergic contact dermatitis and concomitant atopic dermatitis | 22.6 | 0 | 2 |
| The integration of physiologically-targeted skin care in the management of atopic dermatitis: focus on the use of a cleanser and moisturizer system incorporating a ceramide precursor, filaggrin degradation products, and specific "skin-barrier-friend | 22.6 | 0 | 2 |
| Gamisasangja-tang suppresses pruritus and atopic skin inflammation in the NC/Nga murine model of atopic dermatitis | 22.6 | 0 | 2 |
| “Inflammatory skin march”: IL-1–mediated skin inflammation, atopic dermatitis, and psoriasis to cardiovascular events | 22.6 | 0 | 2 |
| Establishing a Role for Interleukin-17 in Atopic Dermatitis-Related Skin Inflammation | 22.6 | 0 | 2 |
| Randomized, double-blinded, placebo-controlled pilot study on the effects of topical blackcurrant emulsion enriched in essential fatty acids, ceramides and 18-beta glycyrrhetinic acid on clinical signs and skin barrier function in dogs with atopic d | 22.6 | 0 | 2 |
| Occupational Contact Dermatitis in Mechanics and Repairers Referred for Patch Testing: Retrospective Analysis From the North American Contact Dermatitis Group 1998-2014. | 22.6 | 0 | 2 |
| Parenting and childhood atopic dermatitis: A cross-sectional study of relationships between parenting behaviour, skin care management, and disease severity in young children. | 22.6 | 0 | 2 |
| Effectiveness of the Healthy Skin Clinic--a randomized clinical trial of nurse-led patient counselling in hand eczema | 22.6 | 0 | 2 |
| Therapeutic benefits in atopic dermatitis care from the patients' perspective: results of the German national health care study 'Atopic Health'. | 22.6 | 0 | 2 |
| Allergic contact dermatitis caused by topical herbal remedies: importance of patch testing with the patients' own products. | 22.6 | 0 | 2 |
| Effects of the Fruit Extract of Tribulus terrestris on Skin Inflammation in Mice with Oxazolone-Induced Atopic Dermatitis through Regulation of Calcium Channels, Orai-1 and TRPV3, and Mast Cell Activation. | 22.6 | 0 | 2 |
| Health-Related Quality of Life, Patient Satisfaction, and Adherence to Treatment in Patients with Moderate or Severe Atopic Dermatitis on Maintenance Therapy: the CONDA-SAT Study | 22.6 | 0 | 2 |
| Use of frozen poloxamer as a base for Itchy skin conditions, including irritant contact dermatitis | 22.6 | 0 | 2 |
| Hand eczema, atopic dermatitis and filaggrin mutations in adult Danes: a registry-based study assessing risk of disability pension | 22.6 | 0 | 2 |
| A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. | 22.6 | 0 | 2 |
| What's up dermatology? A pilot survey of the use of WhatsApp in dermatology practice and case discussion among members of WhatsApp dermatology groups. | 22.6 | 0 | 2 |
| Atopic Dermatitis and Non-atopic Hand Eczema Have Similar Negative Impacts on Quality of Life: Implications for Clinical Significance | 22.6 | 0 | 2 |
| Low basal serum cortisol in patients with severe atopic dermatitis: potent topical corticosteroids wrongfully accused | 22.6 | 0 | 2 |
| Therapeutic patient education in atopic dermatitis: worldwide experiences. | 22.6 | 0 | 2 |
| The role of interleukin-17 in mouse models of atopic dermatitis and contact dermatitis. | 22.6 | 0 | 2 |
| Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all. | 22.6 | 0 | 2 |
| Detecting photoallergic contact dermatitis with patch testing and daylight. | 22.6 | 0 | 2 |
| Chronic hand eczema: a prevalent and challenging skin condition | 22.6 | 0 | 2 |
| Multicenter Patch Testing With Methylchloroisothizoline/Methylisothiazolinone in 100 and 200 ppm Within the International Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Classification of hand eczema: clinical and aetiological types. Based on the guideline of the Danish Contact Dermatitis Group | 22.6 | 0 | 2 |
| Multicenter Patch Testing With Methylisothiazolinone and Methylchloroisothiazolinone/Methylisothiazolinone Within the International Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Atopic dermatitis, house dust mites, and patch testing | 22.6 | 0 | 2 |
| Multicenter Patch Testing With a Resol Resin Based on Phenol and Formaldehyde Within the International Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Signs of atopic dermatitis and contact dermatitis affected by distinct H2-haplotype in the NC/Nga genetic background | 22.6 | 0 | 2 |
| Inhibitory Activity of Allergic Contact Dermatitis and Atopic Dermatitis-Like Skin in BALB/c Mouse through Oral Administration of Fermented Barks of Alnus sibirica | 22.6 | 0 | 2 |
| A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis | 22.6 | 0 | 2 |
| Examination of the skin barrier repair/wound healing process using a living skin equivalent (LSE) model and matrix-assisted laser desorption-ionization-mass spectrometry imaging (MALDI-MSI). | 22.6 | 0 | 2 |
| Influence of topical steroids on intraocular pressure in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). | 22.6 | 0 | 2 |
| Patient education for adults with atopic dermatitis according to the ARNE concept | 22.6 | 0 | 2 |
| Dietary intake of glucono-δ-lactone attenuates skin inflammation and contributes to maintaining skin condition. | 22.6 | 0 | 2 |
| Adherence in Atopic Dermatitis | 22.6 | 0 | 2 |
| Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines | 22.6 | 0 | 2 |
| SKIN BARRIER AND EPIDERMAL DENDRITIC CELLS IN ATOPIC DERMATITIS. | 22.6 | 0 | 2 |
| THE BRIEF COMMENTARY ON GUIDELINES FOR THE MANAGEMENT OF ATOPIC DERMATITIS 2015 - FORCUSING ON THE BIOMARKER AND SKIN CARE. | 22.6 | 0 | 2 |
| Identification of causative chemicals of allergic contact dermatitis using a combination of patch testing in patients and chemical analysis. Application to cases from industrial rubber products | 22.6 | 0 | 2 |
| Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal. | 22.6 | 0 | 2 |
| Statement of the German Contact Dermatitis Research Group (DKG) and the German Dermatological Society (DDG) on liability issues associated with patch testing using a patient's own materials | 22.6 | 0 | 2 |
| Allergic contact dermatitis caused by textile dyes mimicking atopic dermatitis | 22.6 | 0 | 2 |
| Patch testing to a textile dye mix by the international contact dermatitis research group | 22.6 | 0 | 2 |
| Patch testing with a textile dye mix in two concentrations - a multicentre study by the Swedish contact dermatitis research group. | 22.6 | 0 | 2 |
| Occupational allergic contact dermatitis in a 2-year follow-up study: how well does the patient remember the result of patch testing? | 22.6 | 0 | 2 |
| ASSESSMENT OF THE KNOWLEDGE AND ATTITUDES OF NURSES ON THE SKIN CONDITION AND TREATMENT OF DAMAGE | 22.6 | 0 | 2 |
| Hand eczema guidelines based on the Danish guidelines for the diagnosis and treatment of hand eczema | 22.6 | 0 | 2 |
| Routine patch testing in a dermatology clinic of a teaching hospital in Nigeria. | 22.6 | 0 | 2 |
| CHRONIC DERMATITIS OF THE DORSUM OF THE FEET AND SHINS, DUE TO ALLERGIC CONTACT DERMATITIS TO LEATHER PRODUCTS | 22.6 | 0 | 2 |
| Atopic dermatitis-like pruritic skin inflammation caused by feeding a special diet to HR-1 hairless mice | 22.6 | 0 | 2 |
| Classification of hand eczema. | 22.6 | 0 | 2 |
| Physician Survey Regarding Patient Nonattendance at Follow-up Appointments at a University-Affiliated Medical Dermatology Clinic | 22.6 | 0 | 2 |
| Effects of time and recall of patch test results on quality of life (QoL) after testing. Cross-sectional study analyzing QoL in hand eczema patients 1, 5 and 10 years after patch testing | 22.6 | 0 | 2 |
| Anxiety level and severity of skin condition predicts outcome of psychotherapy in atopic dermatitis patients | 22.6 | 0 | 2 |
| Wet wrap therapy in children with moderate to severe atopic dermatitis in a multidisciplinary treatment program. | 22.6 | 0 | 2 |
| As in Atopic Dermatitis, Nonlesional Skin in Allergic Contact Dermatitis Displays Abnormalities in Barrier Function and Ceramide Content | 22.6 | 0 | 2 |
| Patch testing and Histopathology in Thai patients with hyperpigmentation due to Erythema dyschromicum perstans, Lichen planus pigmentosus, and Pigmented contact dermatitis | 22.6 | 0 | 2 |
| Patch Testing for Evaluation of Hypersensitivity to Implanted Metal Devices: A Perspective From the American Contact Dermatitis Society. | 22.6 | 0 | 2 |
| Chitin nanofibrils suppress skin inflammation in atopic dermatitis-like skin lesions in NC/Nga mice | 22.6 | 0 | 2 |
| Patch testing in suspected allergic contact dermatitis due to Emla cream in haemodialyzed patients | 22.6 | 0 | 2 |
| Correlation of skin barrier impairment in atopic dermatitis with aeroallergen sensitization | 22.6 | 0 | 2 |
| Disposable nitrile gloves protect hairdressers from systemic exposure to paratoluenediamine | 22.6 | 0 | 2 |
| New horny layer marker proteins for evaluating skin condition in atopic dermatitis | 22.6 | 0 | 2 |
| Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts | 22.6 | 0 | 2 |
| The study of human skin irritation of a novel herbal skin care product and ingredients by human single closed patch testing | 22.6 | 0 | 2 |
| Topical Glucose Induces Claudin-1 and Filaggrin Expression in a Mouse Model of Atopic Dermatitis and in Keratinocyte Culture, Exerting Anti-inflammatory Effects by Repairing Skin Barrier Function | 22.6 | 0 | 2 |
| MyD88 Contributes to Staphylococcal Enterotoxin B-Triggered Atopic Dermatitis-Like Skin Inflammation in Mice | 22.6 | 0 | 2 |
| Effects of skin care with shower therapy on children with atopic dermatitis in elementary schools | 22.6 | 0 | 2 |
| Significance of Skin Barrier Dysfunction in Atopic Dermatitis | 22.6 | 0 | 2 |
| Eczematous skin reaction from patch testing with aeroallergens in atopic children with and without atopic dermatitis | 22.6 | 0 | 2 |
| Ceramide analogue 14S24 ((S)-2-tetracosanoylamino-3-hydroxypropionic acid tetradecyl ester) is effective in skin barrier repair in vitro. | 22.6 | 0 | 2 |
| Filaggrin null mutations and association with contact allergy and allergic contact dermatitis: results from a tertiary dermatology clinic. | 22.6 | 0 | 2 |
| Epidermal Expression of Host Response Genes upon Skin Barrier Disruption in Normal Skin and Uninvolved Skin of Psoriasis and Atopic Dermatitis Patients | 22.6 | 0 | 2 |
| TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery | 22.6 | 0 | 2 |
| Expression profile of cornified envelope structural proteins and keratinocyte differentiation-regulating proteins during skin barrier repair. | 22.6 | 0 | 2 |
| Is new better than tried and tested? Topical atopic dermatitis treatment in context. | 22.6 | 0 | 2 |
| Inflammation-induced alterations in the skin barrier function: implications in atopic dermatitis. | 22.6 | 0 | 2 |
| Skin barrier impairment correlates with cutaneous Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in adult patients with atopic dermatitis | 22.6 | 0 | 2 |
| Effects of a protein-free oat plantlet extract on microinflammation and skin barrier function in atopic dermatitis patients. | 22.6 | 0 | 2 |
| Contact dermatitis and patch testing for the allergist | 22.6 | 0 | 2 |
| Clinical, biophysical and immunohistochemical analysis of skin reactions to acute skin barrier disruption - a comparative trial between participants with sensitive skin and those with nonsensitive skin. | 22.6 | 0 | 2 |
| Disrupted Skin Barrier is Associated with Burning Sensation after Topical Tacrolimus Application in Atopic Dermatitis | 22.6 | 0 | 2 |
| Histamine Iontophoresis as in vivo Model to Study Human Skin Inflammation with Minimal Barrier Impairment: Pilot Study Results of Application of the Model to a Sensitive Skin Panel | 22.6 | 0 | 2 |
| Eczematous skin reaction to atopy patch testing with cockroach in patients with atopic dermatitis. | 22.6 | 0 | 2 |
| Persistent telangiectasia following patch testing with topical corticosteroids. | 22.6 | 0 | 2 |
| Immune-mediated Skin Inflammation is Similar in Severe Atopic Dermatitis Patients With or Without Filaggrin Mutation | 22.6 | 0 | 2 |
| Patch testing in children--recommendations of the German Contact Dermatitis Research Group (DKG). | 22.6 | 0 | 2 |
| The Influence of Two Different Foam Creams on Skin Barrier Repair of Foot Xerosis: A Prospective, Double-Blind, Randomised, Placebo-Controlled Intra-Individual Study | 22.6 | 0 | 2 |
| Natural peroxisome proliferator-activated receptor-alpha agonist cream demonstrates similar therapeutic response to topical steroids in atopic dermatitis | 22.6 | 0 | 2 |
| An innovative oat-based sterile emollient cream in the maintenance therapy of childhood atopic dermatitis. | 22.6 | 0 | 2 |
| Benefit-risk tradeoff preferences for chronic hand eczema treatments | 22.6 | 0 | 2 |
| Use of a Canine Model of Atopic Dermatitis to Investigate the Efficacy of a CCR4 Antagonist in Allergen-Induced Skin Inflammation in a Randomized Study. | 22.6 | 0 | 2 |
| Efficacy of proactive long-term maintenance therapy of canine atopic dermatitis with 0.0584% hydrocortisone aceponate spray: a double-blind placebo controlled pilot study | 22.6 | 0 | 2 |
| Water resistance profile as a marker of skin barrier damage in atopic dermatitis patients. | 22.6 | 0 | 2 |
| Effects of Blending Oil of Lavender and Thyme on Oxidative Stress, Immunity, and Skin Condition in Atopic Dermatitis Induced Mice | 22.6 | 0 | 2 |
| Pinus densiflora bark extract ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice by regulating Th1/Th2 balance and skin barrier function. | 22.6 | 0 | 2 |
| Steroid-Free Over-the-Counter Eczema Skin Care Formulations Reduce Risk of Flare, Prolong Time to Flare, and Reduce Eczema Symptoms in Pediatric Subjects With Atopic Dermatitis | 22.6 | 0 | 2 |
| An economic evaluation of patch testing in the diagnosis and management of allergic contact dermatitis*1 | 22.6 | 0 | 2 |
| Impact of patch testing on dermatology-specific quality of life in patients with allergic contact dermatitis*1 | 22.6 | 0 | 2 |
| Correlation of clinical features and skin barrier function in adolescent and adult patients with atopic dermatitis | 22.6 | 0 | 2 |
| A three-cohort comparison with videodermatoscopic evidence of the distinct homogeneous bushy capillary microvascular pattern in psoriasis vs atopic dermatitis and contact dermatitis | 22.6 | 0 | 2 |
| The effects of using a moldable skin barrier on peristomal skin condition in persons with an ostomy: results of a prospective, observational, multinational study | 22.6 | 0 | 2 |
| Prescribing success: Developing an integrated prescription and eczema action plan for atopic dermatitis. | 22.6 | 0 | 2 |
| Patch Testing in Children and Adolescents With Suspected Allergic Contact Dermatitis | 22.6 | 0 | 2 |
| A relationship between a psychosomatic and a skin condition in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis | 22.6 | 0 | 2 |
| Contact allergy to topical corticosteroids: a screening study with a corticosteroid mix. Portuguese Contact Dermatitis Research Group (GPEDC). | 22.6 | 0 | 2 |
| Allergic contact dermatitis to topical corticosteroids: clobetasol propionate and clobetasone butyrate | 22.6 | 0 | 2 |
| The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. | 22.6 | 0 | 2 |
| Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. | 22.6 | 0 | 2 |
| Immunoglobulin- and complement-bearing lymphocytes in allergic contact dermatitis and atopic dermatitis (eczema). | 22.6 | 0 | 2 |
| Long-term emollient therapy improves xerosis in children with atopic dermatitis. | 22.6 | 0 | 2 |
| Noninvasive monitoring of plant-based formulations on skin barrier properties in infants with dry skin and risk for atopic dermatitis | 22.6 | 0 | 2 |
| Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis | 22.6 | 0 | 2 |
| Abnormal skin barrier in the etiopathogenesis of atopic dermatitis | 22.6 | 0 | 2 |
| Lactic acid sting test does not differentiate between facial and generalized skin functional impairment in sensitive skin in atopic dermatitis and rosacea | 22.6 | 0 | 2 |
| Guideline-Based Medicine Grading based upon the Guidelines of Care for Ambulatory Atopic Dermatitis Treatment in the United States | 22.6 | 0 | 2 |
| Contact Dermatitis in Atopic Dermatitis Children-Past, Present, and Future | 22.6 | 0 | 2 |
| Intrinsically defective skin barrier function in children with atopic dermatitis correlates with disease severity | 22.6 | 0 | 2 |
| Application of moisturizer to neonates prevents development of atopic dermatitis | 22.6 | 0 | 2 |
| Filaggrin null-mutations increase the risk and persistence of hand eczema in subjects with atopic dermatitis: results from a general population study | 22.6 | 0 | 2 |
| Focus group parental opinions regarding treatment with topical corticosteroids on children with atopic dermatitis | 22.6 | 0 | 2 |
| Long-term Likelihood of Patch Testing, Academic Practice, and American Contact Dermatitis Society Membership Among North American Alexander Fisher Award Winners From 1989 to 2012 | 22.6 | 0 | 2 |
| Atypical Skin Inflammation in a 2.5-Year-Old Girl With Atopic Dermatitis | 22.6 | 0 | 2 |
| Topical corticosteroids for treatment-resistant atopic dermatitis | 22.6 | 0 | 2 |
| Relationship of ceramide–, and free fatty acid–cholesterol ratios in the stratum corneum with skin barrier function of normal, atopic dermatitis lesional and non-lesional skins | 22.6 | 0 | 2 |
| Immunophenotyping of the cutaneous cellular infiltrate after atopy patch testing in cats with atopic dermatitis | 22.6 | 0 | 2 |
| Animal Models for Retinoid Receptor Research: Implications for Epidermal Homeostasis, Skin Barrier Function, Wound Healing, and Atopic Dermatitis | 22.6 | 0 | 2 |
| Moisturizers versus Current and Next-Generation Barrier Repair Therapy for the Management of Atopic Dermatitis | 22.6 | 0 | 2 |
| Patch testing in hand eczema at a tertiary care center | 22.6 | 0 | 2 |
| Topical administration of EGF suppresses immune response and protects skin barrier in DNCB-induced atopic dermatitis in NC/Nga mice | 22.6 | 0 | 2 |
| Statistical analysis plan for the Healthy Hands Project; single centre cluster-randomised clinical trial of a skin care program for the prevention of contact dermatitis in health care workers | 22.6 | 0 | 2 |
| Allergic or irritant contact dermatitis after patch testing with alcohol - that is the point | 22.6 | 0 | 2 |
| Skin Barrier Function in Healthy Subjects and Patients with Atopic Dermatitis in Relation to Filaggrin Loss-of-Function Mutations | 22.6 | 0 | 2 |
| Breach Delivery: Increased Solute Uptake Points to a Defective Skin Barrier in Atopic Dermatitis | 22.6 | 0 | 2 |
| Patch Testing with Formaldehyde 2.0% in Parallel with 1.0% by the Swedish Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Multicentre patch testing with methylisothiazolinone by the European Environmental and Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Patch testing with methylchloroisothiazolinone/methylisothiazolinone 200 ppm aq. detects significantly more contact allergy than 100 ppm. A multicentre study within the European Environmental and Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Skin care in occupational contact dermatitis of the hands | 22.6 | 0 | 2 |
| A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic d | 22.6 | 0 | 2 |
| Contact allergy to topical corticosteroids in children with atopic dermatitis | 22.6 | 0 | 2 |
| Influence of Oral Administration of Lactic Acid Bacteria Metabolites on Skin Barrier Function and Water Content in a Murine Model of Atopic Dermatitis | 22.6 | 0 | 2 |
| The additive value of patch testing with patients' own products at an occupational dermatology clinic | 22.6 | 0 | 2 |
| Delay in medical attention to hand eczema: a follow-up study | 22.6 | 0 | 2 |
| Heritability of Hand Eczema Is Not Explained by Comorbidity with Atopic Dermatitis | 22.6 | 0 | 2 |
| Keratinocyte Expression of A20/TNFAIP3 Controls Skin Inflammation Associated with Atopic Dermatitis and Psoriasis | 22.6 | 0 | 2 |
| Ghrelin protects against contact dermatitis and psoriasiform skin inflammation by antagonizing TNF-α/NF-κB signaling pathways | 22.6 | 0 | 2 |
| Using Patch Testing to Improve Therapeutic Outcome in the Treatment of Hand Eczema in Vietnamese Patients | 22.6 | 0 | 2 |
| Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation | 22.6 | 0 | 2 |
| Comparing Aquaphor to Atopiclair and EpiCeram in Children With Mild to Moderate Atopic Dermatitis | 22.6 | 0 | 2 |
| A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis | 22.6 | 0 | 2 |
| Physicians' perceptions of an eczema action plan for atopic dermatitis | 22.6 | 0 | 2 |
| Bleach Bath Treatment of Adults With Atopic Dermatitis | 22.6 | 0 | 2 |
| The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis | 22.6 | 0 | 2 |
| The effect of aqueous cream BP on the skin barrier in volunteers with a previous history of atopic dermatitis | 22.6 | 0 | 2 |
| Clinical and Cytological Effects of Pimecrolimus Cream 1% after Resolution of Active Atopic Dermatitis Lesions by Topical Corticosteroids: A Randomized Controlled Trial | 22.6 | 0 | 2 |
| Seal, Stopping Atopic Dermatitis and Allergy Study | 22.6 | 0 | 2 |
| A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis | 22.6 | 0 | 2 |
| A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis | 22.6 | 0 | 2 |
| A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| A Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis | 22.6 | 0 | 2 |
| A NOVel Moisturiser for Atopic Dermatitis: Effect on the Skin Barrier | 22.6 | 0 | 2 |
| Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook | 22.6 | 0 | 2 |
| Comparing Cetaphil Restoraderm System Versus Standard Skin Care in Infants | 22.6 | 0 | 2 |
| The Effects of Emollient Therapy on the Skin Barrier | 22.6 | 0 | 2 |
| Pimecrolimus and Epidermal Barrier Function | 22.6 | 0 | 2 |
| Clinical Analysis of the Influence of Using the Skin Care Products on the Diaper Area in Comparison With Using a Cotton Wool Cloth, Moistened With Clear Water on the Skin Physiology of the Newborns From the 1st Day to the 4th Week of Life | 22.6 | 0 | 2 |
| Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management | 22.6 | 0 | 2 |
| Effect of Resveratrol-Enriched Rice on Skin Inflammation and Pruritus in the NC/Nga Mouse Model of Atopic Dermatitis | 22.6 | 0 | 2 |
| Patch Testing in Allergic Contact Dermatitis over the Lower Extremities | 22.6 | 0 | 2 |
| Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab | 22.6 | 0 | 2 |
| PEBBLES study protocol: a randomised controlled trial to prevent atopic dermatitis, food allergy and sensitisation in infants with a family history of allergic disease using a skin barrier improvement strategy | 22.6 | 0 | 2 |
| A Study to Test Safety and Tolerability of a Study Drug Called MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Patients With Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Have Contraindications to Oral Cyclosporine A | 22.6 | 0 | 2 |
| A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Ad | 22.6 | 0 | 2 |
| The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis | 22.6 | 0 | 2 |
| The Effect of Lipopolysaccharide-containing Moisturizing Cream on Skin Care in Patients With Mild Atopic Dermatitis | 22.6 | 0 | 2 |
| Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin | 22.6 | 0 | 2 |
| Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients | 22.6 | 0 | 2 |
| Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD) | 22.6 | 0 | 2 |
| Study of Apremilast in Atopic or Contact Dermatitis | 22.6 | 0 | 2 |
| Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis | 22.6 | 0 | 2 |
| Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis | 22.6 | 0 | 2 |
| VANOS Cream and Skin Barrier Function | 22.6 | 0 | 2 |
| Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Allergic Skin Inflammation (P03475) | 22.6 | 0 | 2 |
| An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis | 22.6 | 0 | 2 |
| Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) | 22.6 | 0 | 2 |
| Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis | 22.6 | 0 | 2 |
| Efficacy of Topical Coal Tar in Children With Atopic Dermatitis | 22.6 | 0 | 2 |
| Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3) | 22.6 | 0 | 2 |
| Skin barrier function in patients with completely healed atopic dermatitis | 22.6 | 0 | 2 |
| A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis | 22.6 | 0 | 2 |
| A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics | 22.6 | 0 | 2 |
| A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis | 22.6 | 0 | 2 |
| A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema | 22.6 | 0 | 2 |
| Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients | 22.6 | 0 | 2 |
| Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema | 22.6 | 0 | 2 |
| Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients | 22.6 | 0 | 2 |
| Atopic Dermatitis (AD) and Food Allergy | 22.6 | 0 | 2 |
| A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists | 22.6 | 0 | 2 |
| Atopic Dermatitis in Atopy Predisposed Infants | 22.6 | 0 | 2 |
| An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis | 22.6 | 0 | 2 |
| An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids | 22.6 | 0 | 2 |
| A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin | 22.6 | 0 | 2 |
| Patch testing with pollens of Gramineae in patients with atopic dermatitis and mucosal atopy | 22.6 | 0 | 2 |
| Cytokinetics of epidermal and dermal cells in allergic contact dermatitis and atopic dermatitis (author's transl) | 22.6 | 0 | 2 |
| Allergic contact dermatitis from topical steroids | 22.6 | 0 | 2 |
| Allergic contact dermatitis in atopic dermatitis | 22.6 | 0 | 2 |
| Topical corticosteroids and Staphylococcus aureus in atopic dermatitis | 22.6 | 0 | 2 |
| Cyclosporin maintenance therapy for severe atopic dermatitis | 22.6 | 0 | 2 |
| Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis from multiple topical corticosteroids | 22.6 | 0 | 2 |
| Allergic contact dermatitis due to ingredients of vehicles. A "vehicle tray" for patch testing | 22.6 | 0 | 2 |
| IgE-positive epidermal Langerhans cells in allergic contact dermatitis lesions provoked in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Interrelationship between biliary dyskinesia and chronic urticaria, chronic eczema and atopic dermatitis | 22.6 | 0 | 2 |
| Epidermal class II human lymphocyte antigen expression in atopic dermatitis: a comparison with experimental allergic contact dermatitis | 22.6 | 0 | 2 |
| Hand eczema: an evaluation of the frequency of atopic background and the difference in clinical pattern between patients with and without atopic dermatitis | 22.6 | 0 | 2 |
| Sodium cromoglycate in childhood atopic dermatitis treatment | 22.6 | 0 | 2 |
| Patch testing in atopic dermatitis | 22.6 | 0 | 2 |
| Behavior of eosinophilic granulocytes in skin exudates in contact dermatitis, urticaria and atopic dermatitis (skin window technic) | 22.6 | 0 | 2 |
| Professional hand eczema and atopic dermatitis | 22.6 | 0 | 2 |
| [The dermatophytic flora surveyed at the Dermatology Clinic of the Tottori University Hospital from 1981 to 1984--statistic analysis of the patients of various clinical types and a comparative study of the ratios of T. rubrum/T. mentagrophytes at de | 22.6 | 0 | 2 |
| Intermittent maintenance therapy in chronic hand eczema with clobetasol propionate and flupredniden acetate | 22.6 | 0 | 2 |
| Determination of suitable concentrations for patch testing of various fragrance materials. A summary of a group study conducted over a 6-year period. Mid-Japan Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Prevalence of respiratory symptoms in children with atopic dermatitis attending pediatric dermatology clinics | 22.6 | 0 | 2 |
| Contact dermatitis. XVI. Patch testing? | 22.6 | 0 | 2 |
| Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood | 22.6 | 0 | 2 |
| Increased "in vivo" lymphocyte blastogenesis in the peripheral blood of patients with atopic dermatitis and allergic contact dermatitis | 22.6 | 0 | 2 |
| Patch testing for contact dermatitis | 22.6 | 0 | 2 |
| Combined skin prick and patch testing enhances identification of food allergy in infants with atopic dermatitis | 22.6 | 0 | 2 |
| Hand eczema in children with atopic dermatitis: a low prevalence? | 22.6 | 0 | 2 |
| Atopic dermatitis, nickel sensitivity and xerosis as risk factors for hand eczema in women | 22.6 | 0 | 2 |
| A retrospective evaluation of patch testing in patients diagnosed with allergic contact dermatitis | 22.6 | 0 | 2 |
| Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Improvement of skin barrier function during treatment of atopic dermatitis | 22.6 | 0 | 2 |
| Coexistence of contact urticaria and contact dermatitis due to pearl oysters in an atopic dermatitis patient | 22.6 | 0 | 2 |
| Contact allergy to aeroallergens in children with atopic dermatitis: comparison with allergic contact dermatitis | 22.6 | 0 | 2 |
| Aeroallergen patch testing for patients presenting to contact dermatitis clinics | 22.6 | 0 | 2 |
| Contact dermatitis due to topical steroids with conceivable cross reactions between topical steroid preparations | 22.6 | 0 | 2 |
| Human and economic impact of allergic contact dermatitis and the role of patch testing | 22.6 | 0 | 2 |
| Allergen specificity and endothelial transmigration of T cells in allergic contact dermatitis and atopic dermatitis are associated with the cutaneous lymphocyte antigen | 22.6 | 0 | 2 |
| Identification of causative chemicals of allergic contact dermatitis using a combination of patch testing in patients and chemical analysis. Application to cases from rubber gloves | 22.6 | 0 | 2 |
| Ranitidine treatment of hand eczema in patients with atopic dermatitis: a double-blind, placebo-controlled trial | 22.6 | 0 | 2 |
| Identification of causative chemicals of allergic contact dermatitis using a combination of patch testing in patients and chemical analysis. Application to cases from rubber footwear | 22.6 | 0 | 2 |
| Airborne contact dermatitis from chromate in cement with recall dermatitis on patch testing | 22.6 | 0 | 2 |
| Allergic contact dermatitis and patch testing in childhood | 22.6 | 0 | 2 |
| Contact dermatitis from thimerosal. 2 years' experience with ethylmercuric chloride in patch testing thimerosal-sensitive patients | 22.6 | 0 | 2 |
| Pseudo-atopic dermatitis. Contact dermatitis due to chrome sensitivity simulating atopic dermatitis | 22.6 | 0 | 2 |
| Treatment of atopic dermatitis in children: the importance of skin care and environmental control | 22.6 | 0 | 2 |
| Squamometry in rating the efficacy of topical corticosteroids in atopic dermatitis | 22.6 | 0 | 2 |
| Skin care and topical steroids | 22.6 | 0 | 2 |
| Topical steroids for atopic dermatitis in primary care | 22.6 | 0 | 2 |
| Why do patients with atopic dermatitis refuse to apply topical corticosteroids? | 22.6 | 0 | 2 |
| Do topical steroids reduce relapses in adults with atopic dermatitis? | 22.6 | 0 | 2 |
| Patch testing with the European standard series and Compositae extracts in patients with airborne contact dermatitis | 22.6 | 0 | 2 |
| Impairment of skin barrier function in NC/Nga Tnd mice as a possible model for atopic dermatitis | 22.6 | 0 | 2 |
| Patient education for adults with chronic eczema | 22.6 | 0 | 2 |
| Patch testing with zinc dibenzyldithiocarbamate. A multicentre study of the Information Network of Departments of Dermatology and the German Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Quantitative analysis of tryptase- and chymase-containing mast cells in atopic dermatitis and nummular eczema | 22.6 | 0 | 2 |
| The results of ingredient patch testing in contact dermatitis elicited by povidone-iodine preparations | 22.6 | 0 | 2 |
| Estimating dilutions for patch testing skin care products: A practical method | 22.6 | 0 | 2 |
| Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis | 22.6 | 0 | 2 |
| Occupational contact dermatitis in nurses with hand eczema | 22.6 | 0 | 2 |
| Expression of 27 KD, 65 KD and 72/73 KD heat shock protein in atopic dermatitis: comparison with those in normal skin and contact dermatitis | 22.6 | 0 | 2 |
| Effect of Ectoin Dermatitis Cream 7% on Skin Hydration and Skin Barrier Function | 22.6 | 0 | 2 |
| Patch testing of nickel sulfate and potassium dichromate with a standardized ready-to-use test system gives highly reproducible results: a double-blind multicentre study | 22.6 | 0 | 2 |
| Patch testing and aeroallergen intradermal testing in suspected allergic contact dermatitis, unclassified endogenous eczema and non-atopic chronic urticaria | 22.6 | 0 | 2 |
| New insights into the role of T cells in atopic dermatitis and allergic contact dermatitis | 22.6 | 0 | 2 |
| Contact dermatitis versus atopic dermatitis | 22.6 | 0 | 2 |
| Reimbursement for patch testing at academic centers: the Achilles' heel of academic contact dermatitis specialists | 22.6 | 0 | 2 |
| Contact dermatitis, nummular eczema, pompholyx; the most common dermatoses of the hands, their diagnosis, differential diagnosis and specific treatment | 22.6 | 0 | 2 |
| The use of decision-analytical modelling in economic evaluation of patch testing in allergic contact dermatitis | 22.6 | 0 | 2 |
| Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm) | 22.6 | 0 | 2 |
| Expression of CD30 on T helper cells in the inflammatory infiltrate of acute atopic dermatitis but not of allergic contact dermatitis | 22.6 | 0 | 2 |
| The effect of two moisturisers on skin barrier damage in allergic contact dermatitis | 22.6 | 0 | 2 |
| Patch testing with maleopimaric acid in an occupational dermatology clinic | 22.6 | 0 | 2 |
| AN EVALUATION OF HAND ECZEMA TREATMENT WITH FLUOCINOLONE ACETONIDE CREAM, AND FLUOCINOLONE ACETONIDE CREAM AND GRENZ RAY | 22.6 | 0 | 2 |
| Patch testing in allergic contact dermatitis caused by topical Chinese herbal medicine | 22.6 | 0 | 2 |
| Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis | 22.6 | 0 | 2 |
| Compare the Skin Barrier Repair Function of Two Ceramide Containing Moisturizers | 22.6 | 0 | 2 |
| Audit of prescribing practices of topical corticosteroids in outpatient dermatology clinics in north Palestine | 22.6 | 0 | 2 |
| Results of standard series patch testing in patients with occupational allergic contact dermatitis | 22.6 | 0 | 2 |
| Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis | 22.6 | 0 | 2 |
| [Topical steroids and tacrolimus for the treatment of atopic dermatitis] | 22.6 | 0 | 2 |
| The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study | 22.6 | 0 | 2 |
| Dynamics of skin barrier repair following topical applications of miconazole nitrate | 22.6 | 0 | 2 |
| Allergic contact dermatitis mimicking atopic dermatitis due to enoxolone in a topical medicament | 22.6 | 0 | 2 |
| Smad3 signal transducer regulates skin inflammation and specific IgE response in murine model of atopic dermatitis | 22.6 | 0 | 2 |
| Prevalence and morphology of hand eczema in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis from corticosteroids: reproducibility of patch testing and correlation with intradermal testing | 22.6 | 0 | 2 |
| Contact dermatitis; practical management and identification of cause without patch testing | 22.6 | 0 | 2 |
| The skin barrier, atopic dermatitis and allergy: a role for Langerhans cells? | 22.6 | 0 | 2 |
| Patient education. Itch--skin care management | 22.6 | 0 | 2 |
| Etiology and prognosis of hand eczema in a dermatology clinic in China: a follow-up study | 22.6 | 0 | 2 |
| Emollients improve treatment results with topical corticosteroids in childhood atopic dermatitis: a randomized comparative study | 22.6 | 0 | 2 |
| Development of numerous nerve fibers in the epidermis of hairless mice with atopic dermatitis-like pruritic skin inflammation | 22.6 | 0 | 2 |
| Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis | 22.6 | 0 | 2 |
| Noninvasive biophysical assessments of the efficacy of a moisturizing cosmetic cream base for patients with atopic dermatitis during different seasons | 22.6 | 0 | 2 |
| Genetics of skin barrier impairment in atopic dermatitis | 22.6 | 0 | 2 |
| Atopic dermatitis and skin barrier function | 22.6 | 0 | 2 |
| A survey of traditional Chinese medicine use in children with atopic dermatitis attending a paediatric dermatology clinic | 22.6 | 0 | 2 |
| Allergic contact dermatitis and the endocannabinoid system: from mechanisms to skin care | 22.6 | 0 | 2 |
| Contact hypersensitivity to topical corticosteroids--frequency of positive reactions in patch-tested patients with allergic contact dermatitis | 22.6 | 0 | 2 |
| The new scoring system for evaluation of skin inflammation extent and severity in patients with atopic dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis from natural rubber latex in atopic dermatitis and the risk of later Type I allergy | 22.6 | 0 | 2 |
| The use of topical corticosteroids in atopic dermatitis in children | 22.6 | 0 | 2 |
| Should topical antibacterials be routinely combined with topical steroids in the treatment of atopic dermatitis? | 22.6 | 0 | 2 |
| Allergic contact dermatitis in patients with atopic dermatitis: A clinical study | 22.6 | 0 | 2 |
| Hand eczema -- clinical patterns and role of patch testing | 22.6 | 0 | 2 |
| An open-label study assessing the safety and efficacy of alitretinoin in patients with severe chronic hand eczema unresponsive to topical corticosteroids | 22.6 | 0 | 2 |
| Relevance of patch testing in hand eczema--comment | 22.6 | 0 | 2 |
| The effect of pimecrolimus on expression of genes associated with skin barrier dysfunction in atopic dermatitis skin lesions | 22.6 | 0 | 2 |
| Dynamics of skin barrier repair following preconditioning by a biotechnology-driven extract from samphire (Crithmum maritimum) stem cells | 22.6 | 0 | 2 |
| Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment | 22.6 | 0 | 2 |
| Effects of "Skin Care School," a parental education program on childhood atopic dermatitis conducted during short hospitalization stays | 22.6 | 0 | 2 |
| Patch testing in allergic contact dermatitis | 22.6 | 0 | 2 |
| Patch testing practices of American Contact Dermatitis Society members | 22.6 | 0 | 2 |
| Japanese cedar pollen as an exacerbation factor in atopic dermatitis: results of atopy patch testing and histological examination | 22.6 | 0 | 2 |
| Impairment of skin barrier function is not inherent in atopic dermatitis patients: a prospective study conducted in newborns | 22.6 | 0 | 2 |
| Skin barrier defects in atopic dermatitis: new treatments? | 22.6 | 0 | 2 |
| Efficacy of sweat-antigen-inactivating skin care products on itching of patients with atopic dermatitis | 22.6 | 0 | 2 |
| Response to treatment with oral alitretinoin in patients with chronic hand eczema that is refractory to treatment with potent topical corticosteroids: experience in 15 patients | 22.6 | 0 | 2 |
| Multicentre Patch Testing with Compositae Mix by the Swedish Contact Dermatitis Research Group | 22.6 | 0 | 2 |
| Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis | 22.6 | 0 | 2 |
| Noninvasive Stratum Corneum Sampling and Electron Microscopical Examination of Skin Barrier Integrity: Pilot Study with a Topical Glycerin Formulation for Atopic Dermatitis | 22.6 | 0 | 2 |
| Two-year assessment of effect of topical corticosteroids on bone mineral density in adults with moderate to severe atopic dermatitis | 22.6 | 0 | 2 |
| IL-25 induces both inflammation and skin barrier dysfunction in atopic dermatitis | 22.6 | 0 | 2 |
| Allergic contact dermatitis caused by dihydroxyacetone - optimal concentration and vehicle for patch testing | 22.6 | 0 | 2 |
| Usefulness of skin-prick tests in children with hand eczema: comparison with their use in childhood and adult eczema | 22.6 | 0 | 2 |
| Oral Lactobacillus paracasei improves skin barrier function recovery and reduces local skin inflammation | 22.6 | 0 | 2 |
| New treatments for restoring impaired epidermal barrier permeability: Skin barrier repair creams | 22.6 | 0 | 2 |
| Beclomethasone dipropionate: a second chance for topical steroids as maintenance therapy in ileal Crohn's disease | 22.6 | 0 | 2 |
| Exacerbation of atopic dermatitis upon alkaline skin care | 22.6 | 0 | 2 |
| Patient education to enhance contact dermatitis evaluation and testing | 22.6 | 0 | 2 |
| Oral administration of glucosylceramide ameliorates inflammatory dry-skin condition in chronic oxazolone-induced irritant contact dermatitis in the mouse ear | 22.6 | 0 | 2 |
| Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis | 22.6 | 0 | 2 |
| Characteristics of patients with hand dermatitis referred to the contact dermatitis unit of a tertiary hospital and impact of patch testing on diagnosis | 22.6 | 0 | 2 |
| Contact dermatitis and atopic dermatitis--rare comorbidity? | 22.6 | 0 | 2 |
| The effect of damaged skin barrier induced by subclinical irritation on the sequential irritant contact dermatitis | 22.6 | 0 | 2 |
| Patch testing in allergic contact dermatitis from minoxidil | 22.6 | 0 | 2 |
| Is soybean patch testing a valid diagnostic tool for adult atopic dermatitis? A comparison of two methods | 22.6 | 0 | 2 |
| Improvement of skin barrier function in atopic dermatitis patients with a new moisturizer containing a ceramide precursor | 22.6 | 0 | 2 |